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INTRODUCTION
Anaesthesia to a parturient is not only unique but also requires highest 
degree of care because the anesthesiologist has to look after two individuals, 
the mother and foetus. In elective caesarean section under spinal anaesthesia 
hypotension has been reported in as many as 85% of patients (1).
Hypotension during spinal anesthesia for caesarean delivery can have 
detrimental  effects  on  both  mother  and  neonate.  These  effects  include 
decreased  utero  placental  blood  flow,  impaired  foetal  oxygenation  with 
asphyxial stress and foetal acidosis and maternal symptoms of low cardiac 
output  such  as  nausea,  vomiting,  dizziness  and  decreased  consciousness. 
Therefore  there  has  been  much  attention  in  the  literature  to  methods  of 
preventing  and  treating  hypotension  in  obstetric  anaesthesia.  Careful 
positioning  with  left  uterine  displacement  and  volume  preloading  with 
crystalloids or colloids has been used to prevent it, but these are not complete 
measures (2, 3) and vasopressor is required to correct hypotension quickly.
Vasopressor  like  Ephedrine,  Mephentermine,  Phenylephrine, 
Metaraminol and Methoxamine are used for treating the hypotension. In this 
study  we  compare  the  efficacy  of  Ephedrine,  Mephentermine  and 
Phenylephrine  in  treating  the  hypotension  for  caesarean  section  and  their 
undesirable side effects.
AIM OF STUDY
To  compare  the  effects  of  Ephedrine,  Mephentermine  and 
Phenylephrine in the management of hypotension during spinal anesthesia for 
cesarean section based on the following parameters
1. Efficacy of vasopressor in treating hypotension,
2. Incidence of undesirable side effects,
3. Effect on neonatal outcome.
SPINAL ANAESTHESIA
Spinal  (subarachnoid/intrathecal)  anaesthesia  is  a  form  of  central 
neuraxial Block in which a temporary interruption of nerve transmission is 
achieved following injection of  local  anaesthetic  and/or  adjuvant  solutions 
into the subarachnoid space. Spinal anaesthesia is one of the most frequently 
employed methods of regional anaesthesia.
Anatomy:
The vertebral canal  extends from the foramen magnum to the sacral 
hiatus. It  is formed by the dorsal spine, pedicles and lamina of successive 
vertebrae (7 cervical, 12 thoracic, 5 lumbar and 5 sacral). The vertebrae are 
held together by a series of overlapping ligaments namely the anterior and 
posterior longitudinal ligaments, ligamentum flavum, interspinous ligament, 
supraspinous ligament and the intervertebral discs.
The spinal cord, a direct continuation of the medulla oblongata begins 
at the upper border of the atlas and terminates distally in the conus medullaris. 
The distal termination, because of the differential growth rates between the 
bony vertebral canal and central nervous system varies from L3 in the infant, 
to the lower border of L1 in the adult.
Surrounding the  spinal  cord  in  the  bony  vertebral  column are  three 
membranes (from within to the periphery), the piamater, arachnoid mater and 
dura mater. The pia mater is a highly vascular membrane that closely invests 
the spinal cord.  The arachnoid mater is a delicate vascular membrane closely 
attached to the outermost dura mater.  Between the two innermost membranes 
is the subarachnoid space. In this space are the cerebrospinal fluid, spinal 
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nerves,  blood  vessels  that  supply  the  spinal  cord  and  the  denticulate 
ligaments. Although the spinal cord ends at the lower border of L1 in adults, 
the  subarachnoid  space  continues  to  S2.  The  outermost  membrane  in  the 
spinal  canal  is  the  longitudinally  organized  fibro  elastic  membrane,  the 
duramater.  This layer is the direct extension of the cranial dura mater and 
extends as the spinal dura mater from the foramen magnum to S2, where the 
filum  terminale  (an  extension  of  the  pia  mater  beginning  at  the  conus 
medullaris) blends with the periosteum of the subdural space which contains 
only small amounts of serous fluids to allow the dura and arachnoid move 
over  each other.   Surrounding the dura mater  is  the epidural  space  which 
extends  from the  foramen magnum to  the  sacral  hiatus.   Posterior  to  the 
epidural  space is the ligamentum flavum which extends from the foramen 
magnum  to  the  sacral  hiatus.   Immediately  posterior  to  the  ligamentum 
flavum is the interspinous ligament.  Extending from the external occipital 
protuberance to the coccyx, posterior to these structures is the supraspinous 
ligament.  Lumbar puncture is routinely done below the L2 vertebrae down to 
the L5-S1 interspace to avoid damaging the spinal cord which ends at the 
lower border of L1 in adults.
Physiology of subarachnoid block:
The cerebrospinal fluid (CSF) is an ultra filtrate of blood plasma with 
which it is in hydrostatic and osmotic equilibrium.  It is a clear, colourless 
fluid found in the spinal and cranial subarachnoid space and in the ventricles 
of the brain.  The average volume in the adult ranges from 120-150 ml of 
which 35 ml is in the ventricles, 25 ml is in the cerebral subarachnoid space 
and 75 ml is in the spinal subarachnoid space.  It is secreted by the choroid 
plexus at a rate of 0.3-0.4 ml/minute.
FIGURE 4: SPINAL CORD ANATOMY
Physical Characteristics of Cerebrospinal Fluid (4):
          pH 7.4
Specific gravity (H20)
At body temperature
At 4°C
1.007
1.0003
Density 1.0003 g/ml
Baricity 1.000
Pressure 8-12 mm Hg/70-80 mm H2O
Cells 3-5/cu.mm
Proteins 20 mg/dl
Glucose 45-80 mg/dl
The cerebrospinal fluid plays an important role in spinal anaesthesia as 
media for dispersion of the local anaesthetic drug to the spinal nerve.  An 
important factor determining the spread of drugs in the subarachnoid space is 
the specific gravity of the injected solution compared with that of CSF.
Mechanism of Spinal Anaesthesia:
Injection of local anesthetic solution into the spinal CSF allows access 
to sites of action both within the spinal cord and the peripheral nerve roots. 
The nerve roots leaving the spinal canal are not covered by epithelium and are 
readily  exposed to  the local  anesthetic  within  the CSF.  Therefore afferent 
impulses  leaving  via  the  ventral  nerve  roots  are  blocked  during  spinal 
anesthesia.  Local  anaesthetics  block  sodium  channels  and  electrical 
conduction in spinal nerve roots.  There are also multiple potential actions of 
local anesthetics within the spinal cord at different sites.  Local anaesthetics 
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can  exert  sodium  channel  block  with  in  the  dorsal  and  ventral  horns, 
inhibiting generation and propagation of electrical activity (5).
Zone of Differential Blockade:
Sensory: In Subarachnoid block, sympathetic fibers are two to three segments 
higher  than  sensory  fibers.  Sympathetic  block  will  be  greater  when  more 
concentrated solutions are used or when adrenaline is added, as this has a 
similar effect.
Motor:  In Subarachnoid block,  the difference between sensory and motor 
block is slight (Two segments).
Order of blocking nerve fibers:
1. Autonomic preganglionic β fibers.
2. Temperature fibers- Cold before warm.
3. Pinprick fibers.
4. Fibers conveying pain greater than pin prick.
5. Touch fibers.
6. Deep pressure fibers.
7. Somatic motor fibers.
8. Fibers conveying vibratory sense and proprioceptic impulses.
During recovery, return of sensibility in the reverse order was assumed, 
but it has been suggested that sympathetic activity returns before sensation.
Spread of Local Anaesthetics in subarachnoid space:
The  local  anaesthetic  solution  is  diluted  by  CSF  and  therefore  its 
original concentration is of less moment than the actual mass of drug injected. 
Spread is also determined by the baricity of the injected solution.  Baricity is a 
ratio  comparing  the  density  of  a  local  anesthetic  solution  at  a  specified 
temperature  to  the  density  of  CSF  at  the  same  temperature.  A hypobaric 
solution has a baricity less than 1.0000 or specific gravity less than 1.0069(the 
mean value of specific gravity). A hyperbaric solution has a baricity greater 
than 1.0000 or specific gravity more than 1.0069.  Hypobaric and Hyperbaric 
solutions  are  prepared  from isobaric  solutions  by  the  addition  of  various 
amounts of sterile distilled water and dextrose respectively. Isobaric solutions 
do not move under the influence of gravity in the CSF. Hyperbaric solutions, 
being  heavier  than  CSF,  settle  to  the  most  dependent  aspect  of  the 
subarachnoid space, which is determined by the position of the patient.  In 
supine  patient,  hyperbaric  solutions  gravitate  to  the  thoracic  kyphosis. 
Hypobaric solution floats up to the nerves innervating the surgical site. The 
major  factors  affecting  height  of  the  block  are  the  baricity  of  the  local 
anaesthetic solution and the dosage of drug injected.
Fate of Local Anaesthetics in Subarachnoid Space:
Following  injection  of  local  anaesthetic  solution  into  subarachnoid 
space, its concentration falls rapidly. The initial steep fall is due to mixing 
with CSF and subsequent absorption into nerve roots and spinal cord. The 
regress  of  local  anaesthetic  solution  following  subarachnoid  injection  is 
primarily  by vascular  absorption with no hydrolysis  or  degradation taking 
place in the CSF.  Depending on the type of the drug used, it is metabolized in 
plasma by pseudo cholinesterase or in the liver. As duration of anaesthesia is 
in the part, a result of the rate of absorption from the subarachnoid space, the 
addition  of  a  vasoconstrictor  to  the  local  anesthetic  solution  will  retard 
absorption of the drug and thus increase the duration of anaesthesia. 
Indications for subarachnoid block:
Spinal anaesthesia can be administered whenever a surgical procedure 
can be done with a sensory level of anesthesia that does not produce adverse 
patient outcome which includes
 Lower abdominal surgeries,
 Lower limb surgeries,
 Urological procedures,
 Obstetric procedures,
 Gynecological surgeries,
 Perineal and rectal surgeries.
Contraindications for subarachnoid block:
Absolute contraindication:
 Patient refusal,
 Local sepsis.
 Relative contraindications:
 Uncorrected coagulopathy,
 Uncontrolled blood loss/shock,
 Fixed cardiac output states,
 Documented allergy to local anesthetics,
 Raised intracranial pressure,
 Neurological disease,
 Major spine deformities/previous surgery on the spine,
 Severe cardiac disease.
Circulatory effects of subarachnoid block (6):
There are six different ways in which subarachnoid block can influence 
the cardiovascular system.
1) Vasodilatation of resistance and capacitance vessels.
2) Block of cardiac efferent sympathetic fibers from T1 to T4 resulting in 
loss of chronotrophic and inotrophic drive and fall in cardiac output.
3) The atrial or Bainbridge reflex causing bradycardia.
4) The operation of Marey’s law causing tachycardia.
5) Depression of vascular smooth muscle and β-adrenergic blockade of 
myocardium with fall in cardiac output, following systemic absorption 
of the local anesthetic drug.
6) Adrenaline  effect  (if  used),  following  absorption,  resulting  in  β 
stimulation  and  associated  rise  in  cardiac  output  and  reduction  in 
peripheral resistance. The overall effect is likely to be a greater fall in 
mean arterial pressure than if adrenaline had not been used.
Slowing of  heart  rate is  caused if  any of  the anterior  roots carrying 
sympathetic cardiac accelerator  fibers are blocked,  as may happen in high 
spinals above T4-5.
A further cause of slow pulse rate is the lowering of blood pressure in 
the right atrium consequent on diminished venous return (Bain Bridge reflex).
SPINAL ANAESTHESIA-TECHNIQUE
The first step in the successful application is proper patient selection. 
This is accomplished by evaluation of the patient through history, physical 
examination, laboratory data and communication with the patient and surgical 
staff about details of the procedure.  Suitable premedication is given to the 
patient before performing the subarachnoid block. Reliable intravenous access 
through a large bore intravenous cannula is mandatory. The administration of 
500-1000 ml of crystalloid or colloid to limit the hypotension that may result 
from the sympathetic block produced by spinal anesthesia has some merit. 
The recommended standards for airway management and emergency drugs 
are  kept  in  readiness.  Spinal  anaesthesia  should  be  administered  to  a 
cooperative patient  who is  placed on a  table  that  can  be tilted  upward or 
downward.
Procedure:
The spinal anaesthetic technique can be broken down into a series of 
steps, the four P`s; Preparation, Position, Projection and Puncture. (7, 8)
Preparation:
Preparation of the equipment and drugs is essential for performing a 
subarachnoid block. The choice of drug is based on the duration of block 
desired, the surgical procedure and patient variables. Spinal needles of various 
diameters with various types of points are available. Spinal needles fall into 
two  main  categories;  those  that  cut  the  dura  and  those  that  designed  to 
separate the dural fibers.  The former includes the Quincke-Babcock needle 
and the latter include the Greene, Whitaker and Sprotte needles.  In order to 
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keep the incidence of post dural puncture headache to a minimum, small bore 
needles with a rounded non cutting bevel are preferred.
Position:
The choice of position of the patient for performing the subarachnoid 
block depends on a number of factors, the proposed surgery being the most 
important. The three primary methods of positioning include lateral decubitus, 
sitting and prone positions, each with its own advantages in specific situation. 
In  the  lateral  decubitus  position,  the  patient  is  placed  with  his/her  back 
parallel to the edge of the operating table nearest the anaesthesiologist, with 
thigh flexed upon the abdomen and neck flexed to allow the forehead to be as 
close to the knees as possible. The sitting position is chosen when low lumbar 
and sacral levels of anaesthesia are adequate for the surgical procedure, when 
obesity or scoliosis make identification of midline anatomy difficult  in the 
lateral decubitus position or when orthopedic problems of the hip and knee 
exist.  The prone position is used primarily for the hypobaric technique for 
rectal and perineal procedures.
Projection and puncture:
The spinal puncture can be performed either by a midline or a Para 
median approach,  usually  at  the L2-L3,  L3-L4, or  L4-L5 interspaces.  The 
procedure is carried out under strict aseptic conditions. The patients back is 
widely prepared with an antiseptic solution and sterile drapes applied. A line 
from the highest point of iliac crest passes through either the spinous process 
of L4 or the L3-L4 interspace. Traditionally the midline approach with patient 
in lateral decubitus position is most popular. Depending on the interspace and 
approach  selected,  a  subcutaneous  skin  wheal  is  raised  over  the  intended 
puncture site with local anesthetic solution. If an introducer is not used, the 
skin and soft tissues are fixed against the bony landmarks which straddle the 
interspace by the second and third fingers of the non dominant hand of the 
anaesthesiologist.  The  needle  is  inserted  in  midline  in  the  middle  of  the 
interspace  with  the  bevel  parallel  to  the  longitudinal  dural  fibers.  After 
traversing  the  skin  and  subcutaneous  tissue,  the  needle  is  advanced  in  a 
slightly  cephalad  direction  with  the  long  axis  of  the  vertebral  canal.  A 
characteristic  change  of  resistance  occurs  as  the  needle  traverses  the 
supraspinous ligament, interspinous ligament, ligamentum flavum, dura and 
pierces  the  arachnoid  which  becomes  quiet  recognizable  as  experience  is 
gained. The stylet is removed and appearance of cerebrospinal fluid at the hub 
of  the  needle  confirms  the  correct  position  of  needle  tip.  The hub of  the 
needle  is  held  firmly  between  the  thumb  and  index  finger  of  the 
anaesthesiologist’s non-dominant hand and the back of that hand is placed 
against  patients  back  to  steady  the  needle,  while  syringe  containing 
anaesthetic solution is firmly attached to the needle. 
After confirming free flow of spinal fluid by aspiration, the anaesthetic 
solution is injected. The patient is placed in desired position. Cardiovascular 
and  respiratory  functions  are  monitored.  Analgesia  is  checked  by  loss  of 
sensation to pin prick.
PHYSIOLOGICAL CHANGES DURING
PREGNANCY (9, 10)
Marked  anatomic  and  physiologic  changes  occur  in  women  during 
pregnancy. 
Body weight and composition: 
The  mean  weight  increase  during pregnancy  is  17% of  prepregnant 
weight (12 kg approximately).
This increase results from:
-Increase in size of the uterus and its contents:
-Uterus : 1 kg,
-Amniotic fluid : 1 kg,    
-Fetus and placenta: 4 kg. 
-Increase in Blood volume and interstitial fluid: 2 kg each 
-Deposition of new fat and protein: 4 kg.
1st Trimester 1-2 kg
2nd Trimester 5-6 kg
3rd Trimester 5-6 kg
-Weight gain:
Metabolism and respiration:
Oxygen consumption:
• Increases by 30% to 40% during pregnancy.
• Progressive rise  is  caused by metabolic  needs  of  fetus,  uterus  and 
placenta and secondarily by increased cardiac and respiratory work.
Anatomy:
• The  thoracic  cage  increases  in  circumference  by  5-7  cm  during 
pregnancy  because  of  both  increase  in  both  anteroposterior  and 
transverse diameter.
• Capillary engorgement of nasal, orapharangeal mucosa, larynx begins 
early  in  the  first  trimester  and  increases  progressively  throughout 
pregnancy.
•  Airway conductance increases, indicating dilatation of larger airways 
below the  larynx.  Factors  contributing to  airway dilatation  include 
direct  effects  of  progesterone,  cortisol,  relaxin  and  enhanced  β 
adrenergic activity induced by progesterone.
• Diaphragm  excursion  is  increased  and  chest  wall  excursion  is 
decreased.
Lung volumes and capacities:
• Tidal volume increases by 45% during pregnancy with half occurring 
during 1st trimester.
• FRC begins to  decrease  by 5th month  and is  decreased to  80% of 
nonpregnant values by term gestation.
• 25% reduction in expiratory reserve volume and 15% reduction in 
residual volume.
Lung volumes Change
Inspiratory reserve 
volume +5%
Tidal volume + 45%
Expiratory reserve volume - 25%
Residual volume - 15%
Lung capacities        Change
    Inspiratory capacity       +15%
    Functional residual capacity        -20%
    Vital capacity     No change
     Total lung capacity         -5%
     Dead space        +45%
     Respiratory rate     No change
     Ventilation:
                Minute ventilation        +45%
                Alveolar ventilation        +45%   
Ventilation:
Minute ventilation increases by 45% during pregnancy with an increase 
evident early in the first trimester. This change results from the increase in 
tidal volume. Although respiratory rate declines slightly during midgestation, 
it is essentially unaltered during pregnancy. 
The ratio of dead space to tidal volume does not change during pregnancy 
and the increase in  alveolar  ventilation is  equivalent  to  minute ventilation 
throughout  the  gestation.  Progesterone  increases  the  sensitivity  of  central 
respiratory centre to CO2 and acts as a direct respiratory stimulant. Estrogen 
also contributes to increased ventilation.
 Anaesthetic significance of respiratory changes: 
1. Airway management is more challenging
• Weight gain and breast engorgement hinder laryngoscopy.
• Swollen mucosa bleeds easily; to avoid intranasal manipulation.
• Use smaller endotracheal tube (6-7mm).
2. Response to anesthetics
• MAC decreased.
• Decreased FRC results in faster induction with insoluble agents.
• Increased VE speeds induction with soluble agents.
• Rapid overdose with loss of airway reflexes.
3. Greater risk of hypoxemia.
• Decreased FRC means less oxygen reserve.
• Increased oxygen consumption. Rapid airway obstruction.
4. Excessive  mechanical  hyperventilation  (PETCo2<24)  may  reduce 
maternal cardiac output and uterine blood flow.
5. Maternal and fetal hypoxemia is associated with pain induced hypo and 
hyper ventilation; can be avoided with effective analgesia.
The Heart and circulation:
Examination:
Elevation of diaphragm shifts the heart anteriorly and to the left during 
pregnancy. The apical impulse moves cephalad to fourth intercostal space and 
laterally to the midclavicular line.
On auscultation accentuation  of  S1 with exaggerated splitting of  S1 
occurs. S2 is changed a little and S3 is easily heard during the later half of 
pregnancy. Grade I or II early to mid systolic murmur is commonly heard at 
the left sternal border and is attributable to cardiac enlargement which results 
in dilatation of tricuspid annulus that causes regurgitation.
ECG: Reveals sinus tachycardia with shortening of PR and uncorrected QT 
intervals during pregnancy. QRS axis shifts to right during first trimester but 
shifts to left during third trimester.
Central hemodynamics:
Cardiac  output  increases  from the  5th week  after  the  last  menstrual 
period and 35% to 40% increase by the end of first trimester. Rise throughout 
the second trimester to reach a maximum of 50% greater than that of non 
pregnant  women  and  does  not  change  during  the  reminder  of  pregnancy. 
Heart  rate  starts  to  increase  by  4th to  5th week  of  pregnancy.  Rises 
approximately 15% to 25% above the nonpregnant values by the end of first 
and second trimester  and no further  changes in  the third trimester.  Stroke 
volume increases approximately 20% between 5th and 8th week of gestation, 
increases by 25% to 30% by the end of second trimester  and remains the 
same.
Organ perfusion:
Uterine  blood  flow  estimated  to  be  from  50-190ml/mt  before 
conception, increases to 700-900ml/mt at term. 90% of this flow peruses the 
intervillous  space  and  10%  to  the  myometrium.  Renal  plasma  flow  is 
increased by 80% at 16-20 weeks but declines to 50% above the nonpregnant 
level  at  term.  Skin perfusion begins  to  increase by 15 weeks and at  term 
increases three to four times to nonpregnant level.
Blood pressure:
Systolic  blood  pressure  is  minimally  affected  by  pregnancy,  with  a 
maximum decline  of  approximately  8% during  early  to  midgestation  and 
return to prepregnant level at term. Diastolic blood pressure falls to a greater 
degree with early to mid gestational decrease of approximately 20%. It also 
returns to prepregnant level at term.
Hemodynamics during labour:
Cardiac output during labour (between uterine contractions) increases 
from prelabour values by approximately 10% in early first stage, 25% in late 
first stage and 40% in second stage. These changes results from increase in 
stroke  volume  with  minimal  changes  in  heart  rate.  Systolic  and  diastolic 
blood pressures are also elevated during late first stage and second stage of 
labour  .A  progressive  elevation  of  sympathetic  nervous  system  activity 
accounts for these changes by increasing myocardial contractility, systemic 
vascular resistance and venous return.
Suppression  of  sympathetic  nervous  system  activity  with  epidural 
analgesia reduces the increase in cardiac output during labour. Cardiac output 
and stroke volume are augmented by an additional 15% to 25% during uterine 
contractions with lesser  increase of  10% to 15% when parturients  receive 
effective analgesia.
  Parameter     Change
Cardiac output       +50%
    Stroke  volume       +25%
    Heart rate        +25%
    Left ventricular end diastolic Volume      Increased
    Left ventricular end  systolic Volume      No change
    Ejection fraction      Increased
    Left ventricular stroke work index      No change
    Pulmonary capillary wedge pressure      No change
    Pulmonary artery diastolic pressure      No change
    Central venous pressure      No change
    Systemic vascular resistance       -20%
Anaesthetic significance of cardiovascular changes:
1. Venodilatation may increase the incidence of accidental epidural vein 
puncture.
2. Healthy parturient will tolerate up to 1500 ml blood loss. Transfusion is 
rarely required.
3. Oxytocin with a free water IV infusion may lead to fluid overload.
4. High hemoglobin level (>14gm %) indicates low volume state caused 
by preeclampsia, hypertension, or inappropriate diuretics.
5. Cardiac output remains high in first few hours postpartum; women with 
cardiac or pulmonary disease remain at risk after delivery.
6. Epidural  block  reduces  cardiac  work  during  labour  and  may  be 
beneficial in some cardiac disease states.
7. Always avoid aortocaval  compression:  70-80% of supine parturients 
with a T4 level develop significant hypotension.   
Haematology:
  The changes that occur during pregnancy are given as follows:
At term:
        Blood volume +45%
        Plasma 
volume
+55%
        RBC volume +30%
        Hemoglobin 11.6gm%
        Hematocrit 35.5%
Gastrointestinal system:
Stomach is displaced upwards towards the left side of the diaphragm 
during pregnancy. This displaces intraabdominal portion of esophagus into the 
thorax leading to reduction in tone of lower esophageal high pressure zone 
(LEHPZ).  This  causes  pyrosis  (heart  burn)  as  a  result  of  reduced  barrier 
pressure (LEHPZ-IGP).
PHARMACOLOGY (11, 12)
EPHEDRINE
Ephedrine  is  a  synthetic,  sympathomimetic,  noncatecholamine  drug 
primarily used as a vasopressor in various clinical situations.
Pharmacodynamics:
Ephedrine  has  direct  effects  on  α,  ß1 and  ß2 receptors  and  indirect 
effects by releasing endogenous nor epinephrine from synaptic storage sites. 
Ephedrine causes increase in systolic and diastolic blood pressure, heart rate 
and cardiac output. Renal and splanchnic blood flows are decreased, whereas 
coronary and skeletal muscle blood flows are increased. Systemic vascular 
resistance  may  be  altered  minimally  because  vasoconstriction  in  some 
vascular beds is offset by vasodilatation (ß2 stimulation) in other areas. These 
cardiovascular  effects  are  due,  in  part,  to  α  receptor  mediated  peripheral 
arterial and venous vasoconstriction. The principal mechanism, however for 
cardiovascular  effects  produced  by  ephedrine  is  increased  myocardial 
contractility due to activation of ß1receptors. In the presence of preexisting ß 
adrenergic blockade,  the cardiovascular  effects of ephedrine may resemble 
responses more typical of α adrenergic stimulation.
Pharmacokinetics:
PO IM    IV
Onset of action:        15-60 mts,       10-20mts, 1-2 mts,
Duration of action:           3-5hrs,       30-60mts, 15-
30mts.
Ephedrine  is  excreted  mostly  as  unchanged  drug  in  urine.  The  rate  of 
excretion is dependent on urinary pH. Excretion is increased in acidic urine. 
Ephedrine is resistant to metabolism by MAO in the gastro intestinal tract, 
thus permitting unchanged drug to be absorbed into circulation after oral 
EPHEDRINE
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administration.  Intramuscular  injection  of  Ephedrine  is  also  acceptable 
because drug induced local vasoconstriction is insufficient to greatly delay 
systemic absorption.
Some Ephedrine is deaminated by MAO in the liver and conjugation 
also occurs. The slow inactivation and excretion of Ephedrine are responsible 
for the prolonged duration of action.
Indication:
 As a vasopressor to treat hypotension caused by sympathetic nervous 
system blockade or hypotension due to inhaled or injected anesthetics.
 As a vasopressor in shock.
 As a chronic oral medication to treat bronchial asthma.
 Nasally  as  nasal  decongestant  to  treat  vasomotor  rhinitis,  acute 
sinusitis, hay fever and acute coryza.
 As an antiemetic.
Contraindication:
 Angle closure glaucoma, Thyrotoxicosis.
 Obstetrics when maternal BP is >130/80.
Precaution:
 Geriatric  patients  may  be  at  a  higher  risk  to  develop  prostatic 
hypertrophy.
 In patients with coronary insufficiency or IHD, hypertension may cause 
intracranial hemorrhage or angina pain.
Side effects:
 CNS: Nervousness, confusion, delirium and hallucinations can occur. 
Anxiety and nervousness may occur after prolonged use.
 CVS:  Precordial  pain  and  excessive  doses  may  cause  hypertension 
sufficient to result in intracranial hemorrhage.
 Genitourinary:  Difficult  and  painful  urination  with  urinary  retention 
can occur in males with Prostatism. Also urine formation is decreased.
Dosage and administration:
 Oral: For Bronchial asthma, Systemic Nasal decongestion:
-12.5-25mg, 4th hourly, not to exceed 150mg in 24hrs.
 Parentral:
• For Bronchial Asthma:
Adults:   25-50mg SC or IM,
      5-25 mg slow IV, if needed repeated every 5-
10mts.
Children: 0.5mg/kg    SC or IM, 6th hourly.
• Vasopressor:
 Adults:    25-50mg IM, SC,
      5-25mg IV, repeated at 5-10mts intervals
Children: 0.5mg/kg IM, IV.
• Nasal decongestion: 0.25% Spray, Topically.
• Antiemetic:     0.5mg/kg IM.
Tolerance:
A second dose of  Ephedrine produces a less  intense systemic blood 
pressure  response  than  the  first  dose.  This  phenomenon  known  as 
Tachyphylaxis  occurs  with  many  sympathomimetics  and  is  related  to  the 
duration of action of these drugs. Tachyphylaxis may also be due to depletion 
of nor epinephrine stores
MEPHENTERMINE
Mephentermine  is  a  synthetic,  sympathomimetic,  noncatecholamine 
drug which is structurally closely related to methyl amphetamine.
Pharmacodynamics:
Mephentermine  indirectly  stimulates  beta  adrenergic  receptors  and 
possibly to a lesser extent alpha adrenergic receptors of sympathetic nervous 
system by releasing noradrenalin from its storage sites. The main effect of 
therapeutic doses of Mephentermine is cardiac stimulation.
Mephentermine  produces  a  positive  inotrophic  effect  on  the 
myocardium. Force of contraction and cardiac output are usually increased 
and may be accompanied by an increased stroke volume in some patients.
Mephentermine  shorten  atrioventricular  conduction  velocity  and  the 
refractory  period  of  the  AV  node  and  increases  ventricular  conduction 
velocity. Although the drug produces a positive chronotrophic effect at the 
sinoatrial node,  this effect  is  usually overcome by increased vagal  activity 
occurring as a reflex to increased blood pressure. Heart rate may be increased, 
decreased or unchanged.
Mephentermine directly dilates the arteries and arterioles in the skeletal 
and mesenteric vascular beds. Venous return to the heart is increased. Also 
increases systolic and diastolic blood pressure by increasing cardiac output. 
Increase in cardiac output is greatest when initial cardiac output is low. When 
cardiac  output  is  high,  increased  peripheral  vascular  resistance  may  be 
responsible for increase in blood pressure.
Mephentermine also dilates the coronary, cerebral, splanchnic and renal 
blood vessels and also stimulates central nervous system.
                                    MEPHENTERMINE
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Pharmacokinetics:      IV      IM
Onset of action Immediate, 5-15 mts,
Duration of action Upto 30 mts. Upto 4 hrs.
It  is  rapidly  metabolized  in  the  body  by  demethylation  in  the  liver 
followed by hydroxylation. It is excreted as unchanged drug and metabolites 
in urine. Excretion is more rapid in acidic urine.
Indication:
 Hypotension due to anesthesia, ganglionic blockade or hemorrhage.
 Shock accompanying myocardial infarction.
Contraindication:
 To treat hypotension caused by Chlorpromazine.
 In combination with MAO inhibitors.
Precautions:
 Hypoxia, Hypercapnia, Acidosis may reduce the effectiveness of and/or 
increase the adverse effects of the drug.
Drug interactions:
 The  vasoconstrictor  effects  of  Mephentermine  may  be  enhanced  by 
concurrent  administration  of  drugs  with  similar  effects  like  Ergot 
alkaloids or Oxytocin.
 Administration  of  Mephentermine  to  patients  who  are  receiving 
cyclopropane  or  halogenated  hydrocarbon  general  anesthetics  may 
increase cardiac irritability which may result in arrhythmias.
Side effects:
 Anxiety,
 Cardiac arrhythmias,
 Hypertension (especially in those with heart disease).
Dosage and administration:
 Hypotension secondary to spinal anesthesia(Prophylaxis)
IM: 30-45mg, administered 10-20 mts prior to anesthesia, operation or 
termination of operative procedure.
 Hypotension secondary to spinal anesthesia(Treatment)
IV: 10-25 mg given as a single dose. May be repeated as needed to 
maintain the desired level of blood pressure.
IV infusion: as 0.1 %( 1mg/ml) solution in 5%Dextrose in water, the 
rate of administration and duration of therapy being adjusted according to 
patient response.
 Shock accompanying Myocardial Infarction:
An  initial  dose  60mg  IV  bolus  followed  by  IV  infusion  of 
0.1%Mephentermine in 5% Dextrose in water or IV administration of serial 
doses of Mephentermine 30-45mg, as necessary. 
PHENYLEPHRINE
Phenylephrine  is  a  synthetic  sympathomimetic  agent.  It  is  a 
vasoconstrictor  and  vasopressor  drug  chemically  related  to  ephedrine  and 
adrenaline.
Pharmacodynamics:  
Phenylephrine is a powerful post – synaptic α1 receptor stimulant with 
little  effect  on ß  receptors  at  the heart.  Phenylephrine  is  a  directly  acting 
sympathomimetic  agent.  After  injection  it  produces  pronounced peripheral 
vasoconstriction and hence increases  in  both systolic  and diastolic  BP.  Its 
action on the heart differs from that of adrenaline and ephedrine, in that it 
slows the heart rate and increases the stoke volume producing no disturbance 
in  rhythm.  At  therapeutic  doses  it  usually  does  not  cause  central  nervous 
system  stimulation.  A major  advantage  of  Phenylephrine  is  the  fact  that 
repeated administration produces comparable effects.
Also acts on α receptors producing vasoconstriction in the skin, mucus 
membranes and the mucosa as well as mydriasis by contracting the dilator 
muscle  of  the  pupil.  Cardiac  output  is  slightly  decreased  and  peripheral 
resistance  is  considerably  increased.  Circulation time is  slightly  prolonged 
and venous pressure is slightly increased.  Venous constriction is not marked. 
Most vascular beds are constricted.  Renal,  cutaneous,  splanchnic and limb 
flows are increased. Pulmonary vessels are constricted and pulmonary arterial 
pressure is raised. Resembles epinephrine, but it has more prolonged action 
and few cardiac effects.
Pharmacokinetics:      IV     IM,SC   Topical
 Onset: immediate, 10-15mts, 15 - 20mts,
Duration: 15- 20mts, 0.5-2hrs for im, 30- 40mts 
50-60mts for sc,
Ophthalmic:
Time to peak effect for mydriasis:  2.5%: 15 – 60mts.
                                                         10%: 10 – 90 mts
                                                   Duration: 2.5%: 3hrs.  
                                                         10 %: 5 – 7hrs.
Phenylephrine is metabolized in the liver by monoamine oxidases. The 
metabolites are excreted in urine.
Indications:
To prevent or treat hypotension during 
 Spinal and inhalation anesthetics, 
 Shock and shock like states,
 Warm septic shock,
 Drug induced hypotension or hypersensitivity reaction or anaphylaxis,
 Weaning from cardiopulmonary bypass.
 To overcome paroxysmal supraventricular tachycardia (high doses to 
produce reflex bradycardia)
 To prolong duration of spinal anesthesia with lignocaine.
 As a vasoconstrictor in regional anesthesia   
Nasal: Nasal congestion due to allergies, sinusitis, common cold or hay fever
Ophthalmologic:  0.12%, 2.5%, 10%:
 Temporary relief of redness of the eye 
 Decongestant and vasoconstrictor
 Treatment of uveitis with posterior synechiae. 
 Open angle glaucoma, Retraction without cycloplegia
 Ophthalmic examination, Fundoscopy. 
Contraindications:
 Severe hypertension.
 Hyperthyroidism.
 Ventricular tachycardia.
Precautions:
 To be used with extreme caution in geriatric pts, severe arteriosclerosis, 
bradycardia,  partial  heart  block,  myocardial  disease,  and 
hyperthyroidism. Anginal pain may be precipitated in pts with angina 
pectoris.
 To be used with caution in patients with Diabetes mellitus or closed 
angle glaucoma.
Side effects:
Phenylephrine is without significant stimulating effects on the central 
nervous system at usual doses
 Extravasations of the drug may cause tissue necrosis. 
 CVS: Reflex bradycardia, arrhythmias.
 CNS:  Headache, excitability and restlessness
 Ophthalmologic: Rebound miosis and decreased mydriatic response in 
geriatric patients, blurred vision.
Dosage and administration:
 Mild to moderate hypotension:
SC or IM: 2 – 5 mg, initial dose should not exceed 5mg. 
IV:  0.2mg,  range  from  0.1  –  0.5mg.  Initial  dose  should  not 
exceed 0.5mg.
 Severe hypotension, shock:
IV infusion: 10 mg in 500ml of 5% dextrose start at 100 180µg/min until 
target BP achieved, and a maintenance rate of 40 - 60µg / min. 
                          PHENYLEPHRINE
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 Hypotension due to central neuraxial blockade:
Prophylaxis: SC or IM: 2 –3 mg administered 3-4 mts before blockade.
Treatment: IV: 0.1-0.2 mg.
 To prolong the duration of spinal anesthesia:
Addition of 2 – 5mg to local anesthetic solution, increase the duration 
of motor block approximately 50% without any increase in the incidence of 
complication such as nausea, vomiting or blood pressure disturbance. 
 Vasoconstrictor for regional analgesia:
Use of 1:2,  00,000 solution of  Phenylephrine to the local  anesthetic 
solution can act as local vasoconstrictor for regional analgesia.
REVIEW OF LITERATURE
1) Dinesh Sahu et al (2003) (13)
They  studied  the  effects  of  bolus  Ephedrine,  Mephentermine, 
Phenylephrine  for  the  maintenance  of  arterial  pressure  during  spinal 
anesthesia for LSCS. Sixty patients in the age group of 20-35 yrs of age with 
ASA-1, 11 are divided into three groups of 20 each as per the study drugs.
Group P:  Phenylephrine 100µg,
Group E:  Ephedrine          6 mg,
Group M: Mephentermine   6 mg.
In this study all  the three vasopressor effectively maintained arterial 
pressure  within  20%  of  baseline  value  though  Phenylephrine  maintained 
better  in  first  6minutes  of  bolus  dose  as  compared  with  Ephedrine  and 
Mephentermine. Phenylephrine causes significant reduction in heart rate after 
the bolus dose. They concluded that all the three vasopressor are effective in 
IV bolus  form  in  maintenance  of   arterial  pressure  within  20%  limit  of 
baseline though Phenylephrine has quicker peak effect and it causes reduction 
in heart rate which may be advantageous in cardiac patients and patients in 
whom tachycardia is Undesirable.
2) Moran DH et al (1991) (14)
They  compared  Ephedrine  and  Phenylephrine  in  the  prevention  of 
maternal  hypotension  following  spinal  anesthesia  for  caesarean  section. 
Patients were randomly assigned to receive either  Ephedrine in 10 mg IV 
bolus injections or Phenylephrine in 80 μg IV bolus injections to maintain 
systolic  BP  above  100  mmHg.  Maternal  venous,  umbilical  artery,  and 
umbilical vein blood gases were measured, and neonatal APGAR scores and 
early neonatal neurobehavioral scale scores were assessed.
There  were  significant  differences  between  the  groups  in  mean 
umbilical artery pH, PCO2   and base deficit, although all values obtained were 
within  normal  limits.  There  were  no  significant  differences  between  the 
groups in the remaining acid-base values, neonatal APGAR scores and early 
neonatal neurobehavioral scale scores, or frequency of maternal nausea and 
vomiting.  Finally  they  concluded  that  Phenylephrine  is  as  effective  as 
Ephedrine in the treatment of maternal hypotension, and when used in small 
increments,  it  appears  to have no adverse neonatal  effects in healthy non-
laboring parturients.
3) Laporta et al (1995) (15)
They compared maternal  and neonatal  catecholamine concentrations, 
following the  use  of  either  Phenylephrine  or  Ephedrine to  treat  a  drop in 
maternal blood pressure after spinal anesthesia for caesarean section. Patients 
were randomly assigned to one of two groups. For decrease in maternal BP 
Group 1: Received Ephedrine 5 mg IV bolus.
Group 2: Received Phenylephrine 40 μg IV bolus.
Maternal vein, umbilical vein and Umbilical artery were taken at the 
time of delivery and analyzed for catecholamine concentrations and blood gas 
values.  They found that Phenylephrine appears to be safe and effective as 
Ephedrine  in  treatment  of  drop in  blood pressure  in  healthy  non-laboring 
parturient undergoing LSCS. The use of Phenylephrine was associated with 
neither significantly lower concentrations of nor adrenaline in both mother 
and neonate.
4) Anna Lee et al (2002) (16)
In their quantitative systematic review, they compared the efficacy and 
safety of Ephedrine with Phenylephrine for the prevention and treatment of 
hypotension during spinal anesthesia for cesarean delivery. Seven randomized 
controlled  trials  were  identified  after  a  systematic  search  of  electronic 
databases,  published articles,  and contact  with authors.  Outcomes assessed 
were  maternal  hypotension,  hypertension  and  bradycardia,  and  neonatal 
umbilical  cord blood pH values and APGAR scores.  For  the  management 
(prevention and treatment) of hypotension, there was no difference between 
Phenylephrine and Ephedrine. Maternal bradycardia was more likely to occur 
with Phenylephrine than with Ephedrine. There was no difference between 
the two vasopressors in the incidence of true fetal acidosis or Apgar score of 
<7 at 1 and 5 min.
This  systematic  review  does  not  support  the  traditional  idea  that 
Ephedrine  is  the  preferred  choice  for  the  management  of  maternal 
hypotension during spinal anaesthesia for cesarean delivery in healthy non 
laboring parturients.
5) Thomas DG et al (1996) (17).
In  their  study  they  compared  the  efficacy  of  bolus  Ephedrine  and 
Phenylephrine for maintenance of arterial pressure during spinal anaesthesia 
for caesarean section. They studied 38 healthy women undergoing elective 
LSCS  under  spinal  anaesthesia  and  were  allocated  randomly  to  receive 
boluses  of  either  Phenylephrine  100  µg  or  Ephedrine  5  mg  for  the 
maintenance of maternal arterial pressure. Maternal arterial pressure (BP) and 
heart rate were measured every minute.
They concluded that in both groups median (range) number of boluses 
of  Ephedrine  and  Phenylephrine  was  similar.  Maternal  systolic  BP  and 
cardiac output changes are similar in both groups, but the mean maximum 
percentage change in maternal HR was larger in Phenylephrine group than in 
the ephedrine group. As a consequence atropine was required in 11/18 women 
in the Phenylephrine group compared with 2/19 in the Ephedrine group. Also 
no neonate had an Apgar of less than 7 at any point of study. They finally 
concluded the use of Phenylephrine for the maintenance of maternal arterial 
pressure during spinal anesthesia for LSCS.
6) Ngan Kee et al (2006) (18)
Historically, Ephedrine has been recommended as the best vasopressor 
in Obstetrics because animal studies showed it causes less reduction in uterine 
blood  flow  compared  with  the  alpha  agonists.  Recent  clinical  evidence, 
however, suggest that this is not as initially thought.
Ephedrine and Phenylephrine have been most investigated. Advantages 
of  ephedrine  include  familiarity,  long  history  and  low  propensity  for 
uteroplacental  vasoconstriction.  Ephedrine,  however,  is  difficult  to  titrate, 
causes  maternal  tachycardia  and  depresses  fetal  pH  and  base  excess. 
Advantages of Phenylephrine include high efficacy, ease of titration and the 
ability to use liberal doses to maintain maternal blood pressure near normal 
and  prevent  nausea  and  vomiting  without  causing  fetal  acidosis. 
Phenylephrine, however, may decrease maternal heart rate and cardiac output 
and few data are available on its use in high risk cases.
They finally concluded based on their observations, that, Phenylephrine 
is the vasopressor that closely meets the criteria for the best vasopressor in 
Obstetrics.
7) Cyna AM et al (2006) (19)
They  studied  the  randomized  controlled  trials  comparing  the 
interventions to prevent hypotension with placebo or alternative treatment in 
women having spinal anaesthesia for cesarean section. They included 75 trials 
in their study from Cochrane pregnancy and childbirth group’s trial register.
They  found  that  Ephedrine  was  significantly  more  effective  than 
control or crystalloid in preventing hypotension. No significant differences in 
hypotension were seen between Ephedrine and Phenylephrine. Phenylephrine 
was  more  effective  than  controls.  High  rates  or  doses  of  Ephedrine  may 
increase the incidence of hypertension and tachycardia.
They  finally  concluded  that  interventions  like  colloids,  Ephedrine, 
Phenylephrine  or  lower  leg  compression  can  reduce  the  incidence  of 
hypotension; none have been shown to eliminate the need to treat maternal 
hypotension during spinal anesthesia for cesarean delivery.
8) Ram Nathan et al (1988) (20)
Maternal  homodynamic  changes  and  neonatal  acid-base  status  were 
assessed in 127 healthy patients undergoing elective cesarean under epidural 
anesthesia  in  their  study.  An impedance  cardiograph was used to  measure 
stroke  volume,  ejection  fraction  and  end  diastolic  volume.  In  addition 
neonatal umbilical  venous and arterial PO2,  PCO2,pH, base excess, lactate, 
pyruvate, excess lactate, and L/P ratio were measured at birth. Patients were 
divided into three groups.
Group 1: Required no vasopressor (normotensive controls)
Group 2: Mean blood pressure decreased from 90 mm Hg.
Group 3: Mean blood pressure decreased from 83 to 62 mm Hg.
Phenylephrine  was  administered  in  100  micrograms  increments  to 
maintain systolic BP greater than 100 mm Hg. They concluded that 
• Transient  maternal  hypotension  does  not  affect  neonatal  acid  base 
status.
• Both Ephedrine and Phenylephrine increase cardiac preload. 
• An alpha agent like Phenylephrine does not cause fetal acidosis when 
used for treating maternal hypotension.
9) David Cooper et al (2002) (21)
They  compared  Phenylephrine  100  µg,  Ephedrine  3mg/ml  and 
Phenylephrine  50  µg/ml  &  Ephedrine  1.5mg/ml  in  combination  given  by 
infusion to  maintain maternal  systemic arterial  pressure at  baseline during 
spinal anesthesia for LSCS. 
They found that fetal acidosis was less frequent in Phenylephrine group 
and less frequent in combination group than in ephedrine. The mean systolic 
arterial pressure was similar in three groups. The mean heart rate was higher 
in  Ephedrine  group  than  in  the  Phenylephrine  group  or  the  combination 
group. Nausea and vomiting was less frequent in Phenylephrine group than in 
ephedrine  group  or  the  combination  group.  They  found  that  giving 
Phenylephrine alone by infusion at caesarean delivery was associated with a 
lower  incidence  of  fetal  acidosis  and  maternal  nausea  and  vomiting  than 
giving Ephedrine alone.  There was no advantage in combining both drugs 
because it increased nausea and vomiting and it did not further improve fetal 
blood gas compared with giving Phenylephrine alone.
They  finally  concluded  that  despite  the  more  favorable  effects  on 
uterine  and  placental  circulations  of  Ephedrine  over  Phenylephrine,  no 
significant differences in fetal acid-base status or lactate concentrations were 
observed. 
10) Lauckner W et al (1978) (22)
10 late pregnant women with hypotension were examined before and 
after the intravenous injection of 30 mg Mephentermine with the method of 
quantitative  sphygmomanometer,  the  bloodless  graphic  registration  of  the 
arterial blood pressure and direct electronic timing of pulse wave velocity. 
Systolic and diastolic blood pressure increased significantly. The cause of this 
rise in arterial blood pressure is the increase in stroke volume exclusively. 
Heart  rate  and  total  peripheral  vascular  resistance  remain  constant.  This 
hemodynamic mode of action is a favorable one in regard to protection of 
uteroplacental  blood  flow.  They  finally  concluded  that  Mephentermine  is 
suitable for the treatment of hypotension during pregnancy.
11) Kansai A et al (2005) (23)
In  their  compared  the  effects  of  IV  infusions  of  Ephedrine  and 
Mephentermine for  maintenance of  maternal  arterial  pressure and neonatal 
outcome in pregnant women receiving subarachnoid block for LSCS. Sixty 
patients who developed hypotension following subarachnoid block for LSCS 
were randomly divided into two groups of 30 each to receive an IV infusions 
of  Ephedrine  and  Mephentermine.  Baseline  hemodynamic  parameters, 
hemodynamic  changes  subsequent  to  the  start  of  vasopressor  infusion, 
duration of hypotension and amount of vasopressor required were statistically 
similar in both groups. Neonatal APGAR scores and acid-base profiles were 
also comparable. They finally concluded that   Mephentermine can be used 
safely and effectively as Ephedrine for the management of hypotension during 
spinal anesthesia in patients undergoing elective LSCS.
12) Casey BM et al (2001) (24)
The 10 point Apgar score has been used to assess the condition and 
prognosis of newborn infants throughout the world for almost 50 years. They 
carried  out  a  retrospective  cohort  analysis  of  151,891  live  born  singleton 
infants without malformations who were delivered at 26 weeks of gestation. 
Paired APGAR scores and umbilical  artery blood pH were determined for 
145,627 infants to assess which test best predicted   neonatal death during the 
first 28 days after birth.  
RESULTS:  For  13,399  infants  born  before  term  (at  26  to  36  weeks  of 
gestation), the neonatal mortality rate was 315 per 1000 for infants with five 
minutes Apgar scores of 0 to 3,as compared with 5 per 1000 for infants with 
five minutes Apgar scores of  7 to 10. For 132,228 infants born at term (37 
weeks of gestation or later),the mortality rate was 244 per 1000 for infants 
with five minute Apgar score of 0 to 3,as compared with 0.2/1000 for infants 
with 5 minute Apgar scores of 7 to 10. The risk of neonatal death in term 
infants with five minute Apgar scores of 0 to 3 was eight times the risk in 
term infants with umbilical artery blood pH values of 7.0 or less. 
They finally concluded that Apgar scoring system remains as relevant 
for the prediction of neonatal survival today as it was almost 50 years ago.
13) Sergio D. Belzarena, TSA et al (2006) (25)
This  study  aimed  at  comparing  ephedrine  and  etilefrine  to  correct 
maternal arterial hypotension during elective Cesarean section under spinal 
anesthesia. In this study 120 pregnant patients who were randomly distributed 
in two equal groups. All patients received spinal anesthesia with bupivacaine, 
fentanyl  and  morphine.  Noninvasive  blood  pressure  and  heart  rate  were 
monitored.  Neonates were evaluated by the Apgar score.  The incidence of 
hypotension,  the  amount  of  vasopressor  needed  to  correct  it  and  adverse 
effects were recorded.
Maternal hypotension was similar in both groups (68%etilefrine group 
and 63% ephedrine group). The first vasopressor dose was enough to correct 
hypotension  in  most  patients,  with  no  difference  between  groups  (66% 
etilefrine, 58% ephedrine). Few patients needed two or more doses to correct 
hypotension or presented reactive hypertension (24% and 10% in etilefrine 
and  34%  and  8%  in  ephedrine  groups,  respectively),  without  statistically 
significant  differences.  There  were  no  differences  in  adverse  effects  and 
neonate tests.
They  finally  concluded  that  with  the  administration  method  and 
selected vasopressor doses; there have been no differences between ephedrine 
and etilefrine used to correct maternal hypotension during Cesarean section 
under spinal anesthesia.
14) Ngan Kee et al (2003) (26)
In  this  study  they have  investigated  the  factors  predicting umbilical 
arterial pH (UA pH) and standard base excess (UA BE) in 337 consecutive 
elective  Caesarean  sections  performed  under  spinal  anaesthesia.  Multiple 
linear  regression analysis  was  performed with UA pH and UA BE as  the 
dependent factors. They found that the significant factors predicting UA pH 
were: use of ephedrine, uterine incision-to-delivery time, maximum decrease 
in systolic  arterial  pressure and the interaction between ephedrine use and 
duration of hypotension.
 The significant factors predicting UA BE were: use of ephedrine and 
the  interaction  between  ephedrine  use  and  duration  of  hypotension.  We 
conclude  that,  in  order  to  minimize  the  risk  of  foetal  acidosis,  ephedrine 
should not be used before delivery, uterine incision-to-delivery time should be 
as short as possible, and alpha-agonists such as metaraminol or Phenylephrine 
should be used to minimize both the magnitude and duration of hypotension.
15)  Smith N et al (1972) (27)
They investigated circulatory effects of single intravenous injections of 
0.75 mg/kg Mephentermine in five healthy volunteer subjects.  Ninety  min 
after  the  first  injection,  atropine  1–2 mg  was  administered  i.v.  and  the 
injection of Mephentermine repeated. Cardiac output was measured beat-by-
beat  with  an  analogue computer-ballistocardio-graph  system,  validated  by 
dye-dilution cardiac outputs. The first injection of Mephentermine increased 
mean  arterial  pressure,  systemic  vascular  resistance,  and  left  ventricular 
minute work, with no change in the other variables. The injection of atropine 
produced  a  sudden  marked  increase in  heart  rate,  cardiac  output,  arterial 
pressure, and left  ventricular work and a fall  in stroke volume. The repeat 
injection  of  Mephentermine caused  considerably  smaller  changes  in  the 
circulation than either previous injection. Atropine thus unmasked the beta-
adrenergic stimulating effects  of  Mephentermine,  as  well  as  a  surprisingly 
prolonged action of the agent. It is suggested that the combination  of atropine 
plus  Mephentermine  be  investigated  as  an  approach to  improved  pressor 
therapy.  Mephentermine  is  relatively  slow in  onset,  with  prolonged  peak 
effects. For a given increase in arterial pressure, it produces much less drastic 
changes in other cardiovascular variables than does Methoxamine. 
16) Mercier FJ et al (2007) (28))
They analyzed the different preventive and curative strategies for the 
management of hypotension during spinal anesthesia for caesarean section. 
Data related  to  hypotension during spinal  anesthesia  for  caesarean section 
were searched in the Medline database. 
Hypotension during caesarean section under spinal anesthesia is very 
frequent (55 to 90%) if not prevented. Crystalloid preload alone is ineffective. 
Colloid  preload  is  effective  but  might  be  better  used  as  a  second  line 
treatment. Ephedrine has been the vasopressor of choice for long, but has a 
weak prophylactic efficacy. In addition, it can induce maternal cardiovascular 
adverse  effects  and  fetal  acidosis.  Prophylactic  Phenylephrine,  with  or 
without ephedrine according to maternal heart rate, is at least as effective as 
ephedrine, with less adverse effects. 
They finally concluded that Hypotension during spinal anesthesia for 
caesarean  section  must  be  systematically  detected,  prevented  and  treated 
without  delay.  The  association  of  vasopressor(s)  (Phenylephrine  with  or 
without  ephedrine)  with  a  rapid  crystalloid  loading  at  the  time  of  spinal 
injection represents the most interesting strategy nowadays.
17) Emmett RS et al (2001) (29)
In this review they assessed the relative efficacy and side effects of 
prophylactic  interventions for  hypotension following spinal  anaesthesia  for 
caesarean  section.  Twenty-five  trials  (1477  women)  meet  their  inclusion 
criteria.  From the data collected they concluded that Ephedrine is associated 
with dose-related maternal hypertension and tachycardia, and fetal acidosis of 
uncertain clinical significance. They concluded that no intervention reliably 
prevents hypotension during spinal anesthesia for caesarean section
18) Ayorinde BT et al (2001) (30)
They evaluated pre-emptive intramuscular in 108 patients undergoing 
elective Caesarean section under spinal anesthesia, assigned to four groups in 
a randomized, double-blind, placebo-controlled study. Group 1 received pre-
emptive Phenylephrine 4 mg i.m., group 2 received Phenylephrine 2 mg i.m., 
group  3  received  ephedrine  45  mg  i.m.,  while  controls  received  an  i.m. 
injection of saline, all given immediately after induction of spinal anesthesia.
 Hypotension was defined as a 25% decrease in mean arterial pressure 
(MAP).  Rescue  intravenous  (i.v.)  boluses  of  ephedrine  were  given  if  the 
patient  was  hypotensive  or  reported  nausea,  vomiting  or  dizziness.  The 
incidence  of  hypotension  was  33%  in  the  Phenylephrine  4  mg  group 
compared with 70% in the control and Phenylephrine 2 mg groups, and 48% 
in the ephedrine 45 mg group. The Phenylephrine 4 mg and ephedrine 45 mg 
groups had a significantly lower percentage reduction in MAP compared with 
controls. They also had a lower total dose of rescue i.v. ephedrine compared 
with  controls.  Neonatal  Apgar  scores  and  umbilical  artery  pH  were 
comparable  in  all  the  three  groups.  They  conclude  that  pre-emptive  i.m. 
Phenylephrine 4 mg and ephedrine 45 mg reduce the severity of hypotension 
and  the  total  dose  of  rescue  i.v.  ephedrine  during  spinal  anesthesia  for 
Caesarean section.
19) Ngan Kee WD et al (2004) (31)
In this randomized, double blinded, controlled trial, they investigated 
the  prophylactic  infusion  of  IV  Phenylephrine  for  the  prevention  of 
hypotension during spinal anaesthesia for cesarean delivery. 
Study group: After SAB, Phenylephrine was infused at 100µg/min for 3 
mts. Then Phenylephrine was infused at 100µg/min whenever systolic BP was 
less than baseline value. Control group: After SAB, Phenylephrine was given 
as  100µg IV bolus  whenever  systolic  BP falls  below the base  line  value. 
Phenylephrine infusion decreased the incidence (23% versus 88%), frequency, 
and magnitude (median minimum SAP, 106 mmHg; range 95-111 mmHg; 
versus median, 80 mmHg; range, 73-93 mmHg) of hypotension of control. 
Heart rate was significantly slower over time in the infusion group compared 
with the control group. In both groups umbilical cord blood gases and Apgar 
scores were similar. They finally concluded that in patients receiving spinal 
anaesthesia for cesarean delivery, a prophylactic infusion of Phenylephrine 
100µg/min,  decreased  the  incidence,  frequency,  and  magnitude  of 
hypotension with equivalent neonatal outcome compared with a control group 
receiving IV bolus Phenylephrine.
20) Warwick D et al (2007) (32)
In this review they discussed about various measures to prevent and 
treat hypotension. In contrast to early reports, recent studies have not shown 
intravenous crystalloid prehydration to be very effective. Colloids are more 
effective but are expensive and have potential adverse effects. Rapid infusion 
of  intravenous  crystalloid  after  induction  (co  hydration)  appears  more 
effective  than  prehydration.  Although  historical  studies  supported  use  of 
ephedrine because of its low propensity to reduce uteroplacental blood flow, 
recent studies support use of α-agonists such as Phenylephrine. Phenylephrine 
is more effective and can be titrated more easily than ephedrine, and it has a 
less depressive effect on fetal pH and base excess. It may be given as boluses 
(50–100  μg)  or  by  infusion  (50–100  μg/min).  A Phenylephrine  infusion 
combined with co hydration is effective for preventing hypotension in most 
patients. Current evidence suggests that infusions are best titrated to maintain 
maternal blood pressure near to baseline values.
21) Afshari A et al (2006) (33)
Spinal  anesthesia  for  caesarean  delivery  may  be  associated  with 
hypotension and fetal acidosis. Prophylactic infusion of Phenylephrine (PE) 
immediately after the induction of anaesthesia appears to be a more effective 
approach than administration of ephedrine to reduce the incidence, frequency 
and severity of hypotension. Furthermore, PE appears to be associated with 
better fetal acid-base status than is ephedrine.
22) Critchley LAH et al (1995) (34) 
They  compared  the  hemodynamic  effects  of  ephedrine  alone  with 
ephedrine  and  colloid  for  the  treatment  of  hypotension produced  by  sub 
arachnoid anaesthesia in 30 patients aged 60–90 yr with fractures of the neck 
of femur. 
Group one received ephedrine as an initial bolus dose of 0.2 mg kg–1 
followed by an infusion of 0.5 mg kg–1 h–1. Group two received ephedrine and 
colloid 8 ml kg–1. If necessary, up to three rescue bolus doses of ephedrine 
(0.1 mg kg–1 and then colloid  solution  (8  ml  kg–1 were given to  maintain 
systolic  arterial  pressure  (SAP)  at  >  75% of  baseline.  Arterial  pressures, 
central venous pressure (CVP), cardiac index (CI), stroke index (SI) and heart 
rate (HR) were measured. In patients receiving ephedrine only,  SVRI, CVP 
and  SI  decreased  and  HR  increased.  Five  patients  in  this  group  required 
colloid,  the  effect  of which  was  to  restore  CVP,  increase  CI  and  SI,  and 
decrease  HR.  In  patients  receiving  ephedrine  and  colloid  solution,  SVRI 
decreased and CI, SI and HR increased. Ephedrine was not a potent arterial 
vasoconstrictor and SAP was maintained mainly by increases in SI and HR. 
23)  Brooker RF et al (1997) (35)
 Using  a  prospective,  double-blind,  randomized,  cross-over  study 
design,  13  patients  received  sequential  infusions  of  epinephrine  and 
Phenylephrine  to  manage  hypotension  after  hyperbaric  tetracaine  (10  mg) 
spinal  anaesthesia.  Blood  pressure,  heart  rate,  and  stroke  volume  were 
recorded at baseline, 5 min after injection of tetracaine, and before and after 
management of hypotension with epinephrine and Phenylephrine. Five min 
after  placement  of  a  hyperbaric  tetracaine  spinal  anaesthesia,  significant 
decrease  in  systolic,  diastolic,  and  mean  arterial  pressures  occurred. 
Phenylephrine was effective at restoring systolic blood pressure after spinal 
anesthesia but  was associated with a decrease in heart  rate  and in cardiac 
output. They finally concluded that Phenylephrine management of tetracaine 
spinal-induced  hypotension  decreases  heart  rate  and  cardiac  output  while 
restoring systolic, mean, and diastolic blood pressure.
24) Critchley LA et al (1994) (36)
In this study they compared three methods of preventing hypotension 
during subarachnoid anesthesia. They attempted to maintain systolic arterial 
pressure (SAP) greater than 75% of baseline by use of i.v. fluids (preloading 
with normal saline 16 ml kg-1 and, if necessary, three subsequent boluses of 
2.5 ml kg-1), an infusion of metaraminol titrated as necessary between 0 and 
5 mg h-1 and an infusion of ephedrine titrated as necessary between 0 and 
120 mg h-1. SAP and mean arterial pressure (MAP), central venous pressure 
(CVP) cardiac index (CI), stroke index (SI) and heart rate (HR). Ephedrine 
failed to maintain SAP in two of 12 patients and was accompanied by several 
cardiovascular  changes:  HR  (12%)  increased  and  SI,  CVP  and  SVRI 
decreased. Treatment failures resulted from failures to maintain SVRI in the 
fluid group and CVP and SVRI in the ephedrine group.
25) Yap JC et al (1998) (37)
They  aimed  to  compare  the  efficacy  of  fluid  preloading  with  two 
recently  recommended  fluid-vasopressor  regimens  for  maintaining  blood 
pressure during subarachnoid anaesthesia in the elderly. Sixty elderly patients 
requiring  surgery  for  traumatic  hip  fractures  received  subarachnoid 
anaesthesia using 0.05 ml/kg of 0.5% heavy bupivacaine.
Hypotension,  i.e.  systolic  arterial  pressure  <  75%  of  baseline,  was 
prevented  or  treated  by:  A--normal  saline  16  ml/kg  plus  intravenous 
ephedrine boluses (0.1 mg/kg); B--normal saline 8 ml/kg plus intramuscular 
depot  ephedrine  (0.5  mg/kg);  or  C--Haemaccel  8  ml/kg  plus  metaraminol 
infusion.  Systolic  arterial  pressure  and  heart  rate  were  recorded.  Systolic 
arterial pressure decreased in all groups after five minutes. Decreases were 
greatest in group A. Heart rate increased by 7% group A and decreased by 9% 
in group C. During the first hour, hypotension was present for 47%, 25% and 
20% of the time in groups A, B and C respectively and overcorrection of 
systolic  arterial  pressure  occurred  in  19%  of  the  time  in  group  C.  they 
concluded  that  treatment  A  was  inadequate  in  preventing  hypotension. 
Treatments  B  and  C  were  more  effective  but  were  associated  with  an 
increased  heart  rate  and  overcorrection  of  systolic  arterial  pressure 
respectively.
26) Turkoz A et al (2002) (38)
Maternal  cardiovascular  changes  and  neonatal  acid-base  status, 
including  lactate  levels,  were  assessed  in  30  healthy  women  undergoing 
elective caesarean section under spinal anaesthesia. Patients were allocated 
randomly to receive IV ephedrine infusion (5 mg/mt immediately after the 
spinal injection or bolus administration of IV ephedrine (10 mg) in case of 
development of hypotension. Maternal and neonatal blood pressure, heart rate 
and  acid-base  status  including  lactate  levels  were  compared  between  the 
groups.  Systolic blood pressure in the bolus group was significantly lower 
when compared to the infusion group. Nausea was observed in one patient 
(6%) in the infusion group and nausea and vomiting were observed in 10 
patients  (66%)  in  the  bolus  group.  In  conclusion,  ephedrine  infusion 
prevented  maternal  hypotension,  reduced  the  incidence  of  nausea  and 
vomiting and led to improved umbilical blood pH during spinal anaesthesia 
for caesarean section.
27) Hall PA et al (1994) (39)
Maternal  cardiovascular  changes  and neonatal  acid base  status  were 
assessed  in  29  healthy  women  undergoing  elective  LSCS  under  spinal 
anaesthesia.  The  patients  were  allocated  randomly  to  one  three  groups  to 
receive  an  IV infusion  of  one  of  the  following.  Ephedrine  1mg/mt  (E1), 
ephedrine 2mg/mt (E2) or Phenylephrine 10µg/mt (P). Invasive arterial BP 
was monitored continuously   and whenever hypotension occurs Ephedrine 
6mg IV bolus was given in groups E1&E2 and Phenylephrine 20µg in group 
P. They found that Phenylephrine was shown to be significantly less effective 
in  maintaining  systolic  BP  within  20%  of  baseline  on  comparing  with 
Ephedrine when administered at this dosage. Neonatal Apgar scores and acid-
base profiles were comparable in all the three groups 
28) Alahutta S et al (1992) (40)
In this study patients were randomized into two groups, to be given 
either Ephedrine or Phenylephrine as a prophylactic infusion supplemented 
with minor boluses to maintain the systolic arterial pressure 20% above the 
baseline values during spinal  anaesthesia for  cesarean section.  They found 
that  both  the  vasopressors  restored  maternal  arterial  pressure  effectively. 
Changes in uterine blood flow occurred during Phenylephrine infusion and 
not during Ephedrine infusion. But the Apgar scores and acid-base values in 
the umbilical cord were within the normal range in both groups. 
MATERIALS AND METHODS
This  study  was  conducted  at  INSTITUTE  FOR  SOCIAL 
OBSTETRICS,  GOVERNMENT  KASTURBA  GANDHI  HOSPITAL, 
Triplicane, attached to  MADRAS MEDICAL COLLEGE,  Chennai-600005 
between  June  2007  to  July  2007  on  90  patients  undergoing  elective  and 
emergency  LSCS.  The  study  was  done  after  getting  institutional  approval. 
Written informed consent was obtained from all the patients included in the 
study.
Study design: 
This study was done in a prospective double blind randomized manner. 
The patients were divided into three groups of 30 each. Patients meeting the 
criteria were incorporated into the study.  Randomization achieved by sealed 
envelope technique.
Group 1: Patients in this group received Inj Ephedrine 6 mg IV 
bolus on developing hypotension.
Group 11: Patients in this group received Inj Mephentermine 6 mg 
IV bolus on developing hypotension.
Group 111: Patients in this group received Inj Phenylephrine 100 
microgram IV bolus on developing hypotension.
Selection of cases:
Inclusion criteria:
Patients  in  age  group  of  18  –  35 years  of  age,  healthy,  ASA I  & II 
patients with singleton full term pregnancy, undergoing elective and emergency 
LSCS were included in the study.
Exclusion criteria:
1. Patients >35 years of age
2. Known hypertensive patients , patients on anti hypertensive drugs
3. Uncontrolled PIH
4. ASA III , IV patients 
5. Multiple Gestation
6. Obese ( > 90 kg)
7. Short stature ( < 140 cm )
Investigations:
1. Hb%, PCV
2. Blood grouping & typing
3. BT, CT, Platelet count
4. Blood sugar, blood urea, Sr. Creatinine
5. Urine albumin, Sugar
Premedication:
Elective surgery:  T. Ranitidine 150 mg PO
T.  Metaclopramide  10  mg  PO  with  sips  of  water  2  hrs 
before surgery
Emergency surgery: Inj. Ranitidine 50 mg IV
   Inj. Metaclopramide 10 mg IV 30 mts before surgery
In the operation theatre appropriate equipment for airway management 
and emergency drugs were kept ready. Patients were shifted to the operation 
theatre.  The  horizontal  position  of  the  operating  table  was  checked.  The 
patients were made to lie supine with a pillow under head. The patients were 
connected  to  non  invasive  sphygmomanometer,  ECG  and  pulse  oximetry 
monitor. Intravenous access was obtained with 18 G IV cannula. All patients 
were preloaded with Ringer lactate (15 ml/Kg) rapidly. The anaesthesiologist 
unaware of  the study drug performed the subarachnoid block and made the 
observations in all the patients involved in the study.
Patients  were placed in right  lateral  position.  Skin over the back was 
prepared  with  antiseptic  solution  and  draped  with  sterile  towel.  The  L3-L4 
interspace was identified and 23 G Quicke-Babcock needle was introduced in 
this space through a midline approach. Once the needle pierced the dura and 
was in the subarachnoid space, stylet was removed and free flow of CSF was 
verified and 1.8cc of  0.5% Bupivacaine was administered intrathecally.  The 
patients were turned supine and immediately a wedge was placed under the 
right flank. Oxygen was administered at a rate of 6 lit/min by a face mask to all  
the patients. 
Inj.  Ergometrine  0.25  mg  slow  IV  and  Inj.  Oxytocin  10  U  in  5% 
Dextrose  were  given  after  clamping  the  cord.  Intravenous  fluids  were 
administered at a rate of 1000 ml / hr throughout the surgery.
After preloading, Heart rate, Systolic BP, Diastolic BP, MAP and SPO2 
were  recorded  and  taken  as  baseline  value.  The  same  parameters  were 
monitored every minute till  the onset  of  hypotension and then recorded for 
every two minutes for ten minutes and thereafter every 5 minutes till the end of 
surgery.
Whenever Hypotension (Fall in Systolic BP < 20 % from baseline value 
or systolic BP < 90 mm Hg) occurred, the study drug was given IV bolus. The 
time of onset of hypotension after SAB, lowest systolic BP recorded, total no. 
boluses and total mg of vasopressor used were recorded. The time of onset of 
bradycardia (HR < 60 / min) was noted and was treated with Inj. Atropine 0.3 
mg IV bolus.
The highest level of sensory block was assessed by pinprick method 5 
min  after  SAB.  The  subarachnoid  block-delivery  interval  was  recorded. 
Neonatal outcome was assessed by the pediatrician by APGAR score at first 
and fifth min.
The incidence of tachycardia (HR > 150 / min) and its time of onset was 
noted. The occurrence of hypertension (> 20 % increase in systolic BP from 
baseline values) was noted. The incidence of nausea and vomiting & its time of 
onset were also noted. Total intravenous fluids given and urine output was also 
noted.
Study material:
A total of 30 cases each were randomly allocated to one of the 
following three groups of study: 
GROUP I : Received Inj Ephedrine 6mg IV bolus
GROUP II : Received Inj Mephentermine 6mg IV bolus
GROUP III : Received Inj Phenylephrine 100µg IV bolus
Statistical method:
The descriptive statistics of the variables studied were represented as 
two-way tables. The categorical factors were represented by the number and 
frequency (%) of cases. The continuous variables were represented by 
measures of central frequency (like mean, median & mode) and deviation 
(say, standard deviation and range). The differences in the proportions of are 
tested for statistical significance using non-parametric Chi-square test for 
variables measured on nominal scale. When testing for two factors, the Mann-
Whitney “U” test or Wilcoxon two sample test (by Kruskal-Wallis “H” test 
which is equivalent to chi-square) was used. Fisher’s exact probability test 
was used wherever indicated. For variables measured on a continuous scale, 
one-way analysis of variance (ANOVA) was employed to elicit the statistical 
significance of variation when three variables were taken together. When 
testing for two groups (pair wise), Student “t” test is used to test for statistical 
significance in the differences of the two means.
OBSERVATION AND RESULTS
Demographic Data:
All the three groups were comparable with respect to their age, height, 
weight, baseline systolic BP, diastolic BP, MAP, heart rate. Also the time to 
develop hypotension, lowest systolic BP recorded, SAB-delivery time were 
comparable in the three groups and was not statistically significant. The level 
of  sensory  blockade  was  comparable  in  all  the  three  groups  and  was  not 
statistically significant.
There was no statistically significant difference among the three groups 
in demographic aspect.
Table 1: Distribution of age of cases by groups$
Age Group 
I Group II Group III p-value
No. of cases
Mean
S.D.
Median
Range
30
25.0
2.91
24.5
21 – 31
30
24.6
3.63
24
18 – 32
30
24.1
2.89
24
19 – 32
0.52
Stat 
Significance
Gr I vs Gr III
Gr II vs Gr III
Gr I vs Gr II
p-value
0.22
0.58
0.58
     $ Not statistically significant
The variation in the mean distribution of cases by age between Group I, 
Group II and Group III was not statistically significant (p=0.52). The same 
was observed between pairs of groups studied.
Table 2: Distribution of height of cases by groups$
Height Group I Group II Group III p-value
No. of cases
Mean
S.D.
Median
Range
30
156.8
5.73
158
145 –
168
30
156.0
5.52
156
145 – 
165
30
154.6
6.39
154
144 – 
165
0.36
Stat. 
Significance
Gr. I vs. Gr. III
Gr. II vs. Gr. III
Gr. I vs. Gr. II
p-value
0.17
0.38
0.58
$ Not statistically significant
The variation in the mean values by height between Group I, Group II 
and Group III was not statistically significant. The same results were 
forthcoming for pair wise comparison between groups.
Table 3: Distribution of weight of cases by groups$
Weight Group 
I Group II Group III p-value
No. of cases
Mean
S.D.
Median
Range
30
61.8
5.17
62
52 – 72
30
61.1
5.66
60
49 – 72
30
61.7
5.25
62
52 – 74
0.35
Stat. Significance
Gr. I vs. Gr. III
Gr. II vs. Gr. III
Gr. I vs. Gr. II
p-value
0.74
0.15
0.44
     $ Not statistically significant
The variation in the mean values by weight between Group I, Group II 
and Group III was not statistically significant. The same results were 
forthcoming for pair wise comparison between groups.  
Table 4: Distribution of cases by groups and sensory block$
Sensory block Group I Group II Group III p-value
No
.
% No
.
% No. %
T4
T5
T6
21
7
2
70.
0
23.
3
6.7
20
5
5
66.
6
16.
7
16.
7
20
9
1
66.
6
30.
0
3.4
0.35
Stat. Significance
Gr. I vs. Gr. III
Gr. II vs Gr. III
Gr. I vs Gr. II
p-value
0.74
0.15
0.44
$ Not statistically significant
The distribution of cases by sensory block grade and groups was not 
statistically significant. Pair wise comparisons of groups also revealed similar 
results.
Table 5: Distribution of Time to develop hypotension by groups$
Time in sec Group. I Group II Group III p-value
No. % No. % No. %
1
2
4
6
8
1
16
7
5
1
3.3
53.3
23.3
16.8
3.3
1
21
8
0
0
3.3
70.0
26.7
0.0
0.0
0
15
13
2
0
0.0
50.0
43.3
6.7
0.0
0.16
Stat. Significance
Gr. I vs. Gr. III
Gr. II vs. Gr. III
Gr. I vs. Gr. II
p-value
0.28
0.16
0.15
$ Not statistically significant
The distribution of time to develop hypotension values between Group I, 
Group II and Group III did not reveal any statistically significant differences. 
The results were similar when the groups were compared in pairs. 
Table 6: Distribution of SAB-Delivery time by groups$
SAB-Delivery time
in mts
Group. I Group II Group III p-value
No. % No. % No. %
4
5
6
7
8
9
10
11
2
1
6
5
6
9
1
0
6.7
3.3
20.0
16.7
20.0
30.0
3.3
0.0
1
2
10
4
5
8
0
0
3.3
6.7
33.3
13.3
16.7
26.7
0.0
0.0
0
1
9
8
4
4
3
1
0.0
3.3
30.0
26.7
13.3
13.3
10.0
3.3
0.53
Stat. Significance
Gr. I vs. Control
Gr. II vs. Control
Gr. I vs. Gr. II
p-value
0.38
0.32
0.82
$ Not statistically significant
The distribution of SAB-Delivery values between Group I,  Group II 
and  Group  III  did  not  reveal  any  statistically  significant  differences.  The 
results were similar when the groups were compared in pairs.
Table 7: Distribution of Lowest Systolic BP values by groups$
Low systolic BP Group. I Group II Group III p-value
Number of cases
Mean
S.D.
Median
Range
30
85.0
5.03
86
75 – 93
30
82.7
6.02
84
71 – 90
30
85.3
4.60
87.5
73 – 90
0.12
Stat. 
Significance
Gr. I vs. Control
Gr. II vs. Control
Gr. I vs. Gr. II
p-value
0.77
0.07
0.12
$ Not statistically significant
The comparison of mean lowest systolic BP values between the three 
groups was not statistically significant. The results were the same for pair 
wise comparisons of groups. 
Table 8: Mean Distribution of cases by groups and baseline HR 
 SBP, DBP, MAP$
At Baseline Group I
(n=30)
Group 
II
(n=30)
Group III
(n=30)
p-value
Heart rate
Mean
SD
86.4
12.25
83.9
10.39
90.1
13.62
0.14
Systolic BP
Mean
SD
119.6
7.68
119.2
8.46
119.5
8.45
0.98
Diastolic 
BP
Mean
SD
74.0
6.38
78.8
7.58
76.7
7.43
0.07
MAP value
Mean
SD
89.2
5.57
92.3
7.11
90.3
6.93
0.19
          $ Not statistically significant
The mean distribution of anthropometric values of the heart rate, 
systolic BP and MAP at baseline between the three groups was not 
statistically significant. . The results were the same for pair wise comparisons 
of groups.
Haemodynamic variables:
Table 9: Mean Distribution of cases by groups and HR
HR Group I
(n=30)
Group II
(n=30)
Group III
(n=30)
p-value
Base line
Mean
SD
86.4
12.25
83.9
10.39
90.1
13.62
0.14
HP(VP given)
Mean
SD
90.7
25.52
90.9
18.47
87.6
17.93
0.24
2 mts after VP
Mean
SD
93.1
21.21
93.8
18.3
83.2
17.8
0.04*
4-mts
Mean
SD
93.7
     19.49
93.8
20.50
91.3
12.64
0.83
6-mts
Mean 96.2 99.0 94.6 0.58
SD 17.58 18.16 13.10
8-mts
Mean
SD
96.5
17.24
98.6
15.31
94.0
12.76
0.51
10-mts
Mean
SD
97.2
15.36
97.2
15.51
92.7
13.07
0.40
15-mts
Mean
SD
96.6
16.31
96.1
15.42
92.1
12.53
0.43
20-mts
Mean
SD
95.6
15.96
96.7
15.88
93.8
12.17
0.74
25-mts
Mean
SD
N=29
96.3
15.31
N=30
95.8
14.41
N=30
93.1
11.98
0.63
30-mts
Mean
SD
N=28
95.5
12.38
N=30
96.1
14.67
N=29
91.9
11.94
0.42
*statistically significant
The mean value of heart rate was generally the highest in Group II followed by 
Group I and Group III. The mean variation of heart rate values between the three groups 
was statistically significant at 2mts. Pair wise comparison of groups showed that the 
differences in mean values were statistically significant between Group II and III and 
between Group I and III at 2-mts.
Table 10: Mean Distribution of cases by groups and Systolic BP$
SYSTOLIC BP Group I
(n=30)
Group II
(n=30)
Group III
(n=30) p-value
Base line
Mean
SD
119.6
7.68
119.2
8.46
119.5
8.45 0.98
HP(VP given)
Mean
SD
85.3
5.08
82.7
6.11
85.7
5.21
0.07
2 mts after VP
Mean
SD
104.6
16.99
105.5
12.20
111.9
12.64
0.10
4-mts
Mean
SD
114.2
16.04
108.7
10.69
112.7
13.25
0.26
6-mts
Mean
SD
112.6
12.33
112.2
11.11
113.9
9.16
0.81
8-mts
Mean
SD
110.9
8.79
112.6
10.55
114.3
11.76
0.45
10-mts
Mean
SD
112.0
10.02
113.5
10.39
114.6
11.00
0.63
15-mts
Mean
SD
111.5
9.25
111.5
10.64
114.7
9.96
0.37
20-mts
Mean
SD
111.8
7.05
112.7
9.83
115.1
9.91
0.35
25-mts
Mean
SD
N=29
110.0
9.02
N=30
110.1
21.82
N=30
114.7
10.57
0.38
30-mts
Mean
SD
N=28
114.9
7.80
N=30
115.2
11.44
N=29
116.0
9.53
0.90
$ Not statistically significant
The distribution of mean values of systolic BP was generally the 
highest in Group III especially after 6 mts. The variation in mean systolic 
values between the three groups was not statistically significant at any time 
point studied.
Table 11: Mean Distribution of cases by groups and Diastolic BP
DIASTOLIC 
BP
Group I
(n=30)
Group II
(n=30)
Group III
(n=30)
p-value
Base line
Mean
SD
74.0
6.38
78.8
7.58
76.7
7.43
0.07
HP(VP given)
Mean
SD
50.6
9.95
51.8
9.22
49.3
9.82
0.62
2 mts after VP
Mean
SD
59.6
12.56
66.0
11.83
69.0
12.03
0.01*
4-mts
Mean
SD
64.6
13.79
66.4
8.63
68.0
14.29
0.54
6-mts
Mean
SD
64.5
10.33
68.6
10.10
66.2
13.62
0.39
8-mts
Mean
SD
64.8
9.32
70.2
8.03
66.5
13.73
0.15
10-mts
Mean
SD
65.8
9.03
70.5
9.66
69.0
11.2
0.19
15-mts
Mean
SD
65.4
9.54
69.8
9.50
68.5
9.94
0.20
20-mts
Mean
SD
64.9
8.15
70.5
7.97
69.7
9.65
0.03*
25-mts
Mean
SD
N=29
64.4
8.65
N=30
72.2
10.39
N=30
68.5
9.22
0.009*
30-mts
Mean
SD
N=28
65.3
9.45
N=30
71.8
9.93
N=29
71.9
8.97
0.01*
* Statistically significant
The mean value of diastolic BP was greater in Group III than Group I 
or Group II values at 2nd and 4th mt. The variation in the mean values of 
diastolic BP between the three groups was statistically significant at 2-mts 
(p=0.01) and between 20 and 30 minutes. Pair wise comparison of groups 
revealed that the mean differences were statistically significant between 
Group I and Group II at 8-mts (p=0.02). 
Table 12: Mean Distribution of cases by groups and MAP
MAP Group I
(n=30)
Group II
(n=30)
Group III
(n=30)
p-value
Base line
Mean
SD
89.2
5.57
92.3
7.11
90.3
6.93
0.19
HP(VP given)
Mean
SD
62.2
7.69
62.1
7.47
61.4
7.33
0.89
2 mts after VP
Mean
SD
74.6
13.38
83.7
7.60
83.3
11.7
0.003*
4-mts
Mean
SD
81.0
13.28
71.8
5.95
82.8
13.31
<0.001*
6-mts
Mean
SD
80.6
10.11
80.9
8.47
82.1
10.74
0.83
8-mts
Mean
SD
80.2
8.11
83.1
6.79
82.5
12.50
0.46
10-mts
Mean
SD
81.2
8.43
84.4
9.46
84.2
10.11
0.35
15-mts
Mean
SD
80.8
8.42
84.2
9.09
83.9
9.00
0.26
20-mts
Mean
SD
80.5
6.82
84.8
8.13
84.9
9.07
0.054
25-mts
Mean
SD
N=29
79.6
7.68
N=30
85.3
9.65
N=30
83.9
8.66
0.04*
30-mts
Mean
SD
N=28
82.0
7.03
N=30
85.4
9.16
N=29
86.6
8.40
0.10
* Statistically significant
The mean differences in MAP values between the three groups were 
statistically significant at 2-mts (p=0.003), 4 mts (p<0.001) and 25-mts 
(p=0.04). The pair wise comparisons between Group I and Group II was 
statistically significant at 25-mts (p=0.02) and between Group I and Group III 
at 30-mts (p=0.03). 
Table 13: Distribution of Bolus dose required by groups
Bolus dose Group I Group II Group III p-valueNo. % No. % No. %
One
Two
Three
21
8
1
70.0
26.7
3.3
23
7
0
76.7
23.3
0.0
27
3
0
90.0
10.0
0.0
0.23
In Group-1: 70% of patients required one, 27% of patients required two 
and 3% of patients required three bolus doses to maintain systolic pressure 
within 20%limit of basal value.
In  Group-11:  77%  of  patients  required  one  and  23%  of  patients 
required two  bolus doses to maintain systolic pressure within 20%limit of 
basal value.
In  Group-111:  90%  of  patients  required  one  and  10%  of  patients 
required two  doses to maintain systolic pressure within 20%limit of basal 
value.
Side effects:
Table 14: Distribution of cases by groups and co-morbid conditions$
Co-morbid 
conditions
Group I Group II Group III
No. % No. % No. %
Brachycardia
Yes
No
5
25
16.
7
83.
3
3
27
10.0
90.0
7
23
23.3
76.7
Tachycardia
Yes
No
1
29
3.3
96.
7
1
29
3.3
96.7
0
30
0.0
100.0
Hypertension
Yes
No
2
28
6.7
93.
3
0
30
0.0
100.
0
0
30
0.0
100.0
Bradycardia: 17% of patients in group-1, 10% of patients in group-11 
and 24% of patients in group-111 developed bradycardia and was 
subsequently treated with Inj.Atropine 0.6mg IV bolus.
Tachycardia: 4% of patients in group-1&11 developed tachycardia.
Hypertension: 7% of patients in group-1 developed hypertension.
Table 15: Distribution of cases by groups and conditions
Conditions Group I Group II Group III
No. % No
.
% No
.
%
Nausea &Vomiting
Yes
No
5
25
16.
7
83.
3
6
24
20.
0
80.
0
3
27
10.0
90.0
5% in group-1, 6% in group-11, 3% in group-111 developed nausea and 
vomiting.
Neonatal outcome:
Table 16: Distribution of APGAR-1 by groups$
APGAR-1 Group. I Group II Group III p-value
No
. % No. % No. %
6
7
2
28
6.7
93.
3
2
28
6.7
93.
3
1
29
3.3
96.
7
0.81
Stat. 
Significance
Gr. I vs. Gr. III
Gr. II vs. Gr. III
Gr. I vs. Gr. II
p-value
1.00
1.00
1.00
$ Not statistically significant
Table 17: Distribution of APGAR-5 by groups$
APGAR-5 Group. I Group II Group III p-value
No
. % No. % No. %
7
8
2
28
6.7
93.
3
1
29
3.3
96.
7
1
29
3.3
96.
7
0.77
Stat. 
Significance
Gr. I vs. Gr. III
Gr. II vs. Gr. III
Gr. I vs. Gr. II
p-value
1.00
1.00
1.00
$ Not statistically significant
The distribution of APGAR scores at 1 and 5 minutes between the three 
groups was not statistically significant. The pair wise comparisons too 
revealed similar results. At 5 mt no neonate had an Apgar score of less than 7. 
DISCUSSION
After  subarachnoid  block  for  caesarean  section,  hypotension  can  be 
minimized  by  the  use  of  IV  fluid  preload,  avoidance  of  aortocaval 
compression and judicious use of vasopressor agent. It has been shown that 
the percentage decrease in placental  perfusion is  related to  the percentage 
reduction in maternal arterial pressure and not to the absolute reduction in 
pressure (41).  For  the  purpose  of  this  study,  hypotension  was  defined  as  a 
decrease in arterial pressure greater than 20% from baseline systolic pressure.
Ephedrine and Mephentermine have got a mixed action directly as well 
as  indirectly  on  α  and  ß  receptors,  whereas  Phenylephrine  has  pure  α 
receptors activity. 
Haemodynamic variables:
Heart rate:
In  our  study  the  mean  value  of  heart  rate  was  generally  highest  in 
Mephentermine  Group  followed  by  Ephedrine  and  Phenylephrine  Groups. 
Also  the  mean  variation  of  heart  rate  between  the  three  groups  was 
statistically  significant  at  2  mts.  Pair  wise  comparison  between  the  three 
groups were also statistically significant between the three groups at 2 mts 
after administration of the vasopressor. In spinal anaesthesia, since there is 
decreased venous return,  decreased venous pressure  and a  decreased right 
heart pressure thus slowing of the heart rate is expected on the basis of the 
Bain bridge reflex. Bradycardia is also expected in high spinal, probably due 
to some paralysis of the cardio-accelerator nerves. We found that the maternal 
heart  rate  was  slower  with  Phenylephrine  than  with  Ephedrine  and 
Mephentermine.  This  is  consistent  with  the  mechanism of  action  of  these 
drugs that the decrease in heart rate found in Phenylephrine group was due to 
pure α receptor activity compared with Ephedrine and Mephentermine as they 
had got a mixed action directly as well as indirectly on α and ß receptors. 
Similar  results  were  seen  in  many  studies  which  was  consistent  with  our 
study.
In the study done by Dinesh Sahu et al (13) Phenylephrine was found to 
cause  significant  reduction  in  heart  rate  after  the  bolus  dose.  In  the 
quantitative systematic review done by  Anna Lee et  al (16) they found that 
maternal bradycardia was more likely to occur with Phenylephrine than with 
Ephedrine.  Also  Thomas DG et  al (17)  on comparing the efficacy of  bolus 
Ephedrine  and Phenylephrine,  they found that  mean maximum percentage 
change  in  maternal  HR  was  larger  in  Phenylephrine  group  than  in  the 
ephedrine group. As a consequence atropine was required in eleven out of 
eighteen  women  in  the  Phenylephrine  group  compared  with  two  out  of 
eighteen women in the Ephedrine group
In  the  systematic  review  by  Ngan  Kee et  al (18)  he  concluded  that 
Phenylephrine may decrease maternal heart rate and cardiac output. In David 
Cooper  et  al’s (21) study  on  comparing  the  effects  of  Ephedrine  and 
Phenylephrine when administered alone and in combinations they found that 
mean heart  rate was higher  in  Ephedrine group than in the Phenylephrine 
group or the combination. In the study done by  Lauckner W et al  (22), the 
efficacy of IV Mephentermine in treating hypotension was studied in 10 late 
pregnant women undergoing elective LSCS under SAB and they found that 
heart rate and total peripheral vascular resistance remain constant. 
 Kansai  A et  al  (23) on  comparing  the  effects  of  IV  infusions  of 
Ephedrine and Mephentermine for maintenance of maternal arterial pressure 
they found that the baseline haemodynamic parameters, and haemodynamic 
changes  subsequent  to  the  start  of  vasopressor  infusion,  were  statistically 
similar in both groups. In  Ngan Kee WD et al’s (31) study on comparing the 
effects of prophylactic infusion and bolus Phenylephrine they found that heart 
rate was significantly slower over time in the infusion group compared with 
the control group
On  comparing  the  haemodynamic  effects  of  ephedrine  alone  with 
ephedrine  and  colloid  for  the  treatment  of  hypotension produced  by 
subarachnoid anesthesia in 30 patients aged 60–90 yr with fractures of the 
neck of femur Critchley LAH et al  (34) they found that in patients receiving 
ephedrine  only, SVRI,  CVP and  SI  decreased  and  HR  increased  and  in 
patients receiving ephedrine and colloid solution, SVRI decreased and CI, SI 
and HR increased. They finally concluded that Ephedrine was not a potent 
arterial vasoconstrictor and SAP was maintained mainly by increases in SI 
and HR. 
In  the  study  done  by  Brooker  RF et  al  (35)  they  found  that 
Phenylephrine was associated with a decrease in heart  rate  and in  cardiac 
output.  In  the  study  done  by  Critchley  LA et  al  (36)  Ephedrine  was 
accompanied  by  increase  in  HR  in  12%  of  cases. Yap  JC et  al  (37) on 
comparing  the  efficacy  of  fluid  preloading  with  IV Ephedrine,  IM depot 
Ephedrine  and  Metaraminol  infusion  for  maintaining  blood  pressure  they 
found that heart rate increased by 7% in group receiving IV bolus ephedrine 
and IM depot Ephedrine was effective but was associated with an increase in 
heart rate.
Blood pressure:
The  systolic,  diastolic  and  mean  arterial  pressure  were  decreased 
statistically  significant  at  the onset  of  hypotension and increased after  the 
bolus dose of drug in all the three groups. The pressures generally remained 
high  in  Mephentermine  and  Phenylephrine  groups  when  compared  with 
Ephedrine  group.  Systolic  blood  pressure  was  generally  highest  in 
Phenylephrine  group  immediately  after  the  administration.  The  diastolic 
blood pressure was also greater in Phenylephrine group when compared with 
ephedrine and Mephentermine groups, especially after 2nd and 4th minute, after 
administration of the drug. In Ephedrine group the diastolic blood pressure 
was generally less throughout the study period, when compared with other 
two  drugs.  MAP was  also  less  in  Ephedrine  group  when  compared  with 
Mephentermine  and  Phenylephrine  groups.  The  mean  differences  in  MAP 
between  the  three  groups  were  statistically  significant  at  2nd,  4th and  25th 
minute after the administration of vasopressor. This finding is consistent with 
the onset of action and efficacy of the drug that Phenylephrine has quicker 
onset of action and better maintenance of arterial pressures when compared 
with the other two drugs. 
Dinesh  Sahu et  al (13) studied  the  effects  of  bolus  Ephedrine, 
Mephentermine,  Phenylephrine  for  the  maintenance  of  arterial  pressure 
during spinal anesthesia for LSCS. In their study all  the three vasopressor 
effectively maintained arterial pressure within 20% of baseline value though 
Phenylephrine maintained better in first 6minutes of bolus dose as compared 
with Ephedrine and Mephentermine and Phenylephrine has a quicker peak 
effect. This finding is consistent with our study.
 Laporta  et  al  (15) compared  maternal  and  neonatal  catecholamine 
concentrations, following the use of either bolus Phenylephrine or Ephedrine 
to  treat  a  drop  in  maternal  blood  pressure  after  spinal  anaesthesia  for 
caesarean  section.  They  found  that  Phenylephrine  appears  to  be  safe  and 
effective as Ephedrine in treatment of drop in blood pressure in healthy non-
laboring parturient undergoing LSCS
Anna Lee et al (16) in their quantitative systematic review, they found 
that for the management (prevention and treatment) of hypotension, there was 
no  difference  between  Phenylephrine  and  Ephedrine  and  both  effectively 
maintained the systolic BP within 20% of baseline values. Thomas DG et al 
(17) in their study compared the efficacy of bolus Ephedrine and Phenylephrine 
for maintenance of arterial pressure during spinal anaesthesia for caesarean 
section and found that maternal systolic BP and cardiac output changes are 
similar in both groups
 Cyna AM et al (19) studied the randomized controlled trials comparing 
the  interventions  to  prevent  hypotension  during  spinal  anaesthesia  for 
cesarean section. From 75 trials they found that Ephedrine was significantly 
more effective than control or crystalloid in preventing hypotension. There 
were  no  significant  differences  between  Ephedrine  and  Phenylephrine  in 
treating hypotension. Similar results were obtained from our study also. Ram 
Nathan et al (20) assessed the maternal homodynamic changes and neonatal 
acid-base status in 127 healthy patients undergoing elective cesarean under 
epidural  anesthesia  and  concluded  that  both  Ephedrine  and  Phenylephrine 
increase  cardiac  preload  and  effectively  maintained  the  systolic  blood 
pressure within 20% of baseline values. 
 David Cooper et al  (21) compared Phenylephrine 100 µg, Ephedrine 
3mg/ml and   Phenylephrine 50 µg/ml & Ephedrine 1.5mg/ml in combination 
given by infusion to maintain maternal systemic arterial pressure at baseline 
during spinal anesthesia for LSCS and found that the mean systolic arterial 
pressure was similar in three groups. Lauckner W et al (22) studied the effects 
of IV Mephentermine in 10 late pregnant women with hypotension after SAB 
and found that Systolic and diastolic blood pressure increased significantly. 
The cause of this rise in arterial blood pressure is due to increase in stroke 
volume exclusively and no significant changes occurred in heart rate. They 
finally  concluded  that  Mephentermine  is  suitable  for  the  treatment  of 
hypotension during pregnancy.
Kansai A et al  (23) compared the effects of IV infusions of Ephedrine 
and Mephentermine for maintenance of maternal arterial pressure receiving 
subarachnoid  block  for  LSCS  and  found  that  baseline  hemodynamic 
parameters,  hemodynamic  changes  subsequent  to  the  start  of  vasopressor 
infusion,  were  statistically  similar  in  both  groups.  Smith  N et  al  (27) 
investigated circulatory effects of single intravenous injections of 0.75 mg/kg 
Mephentermine  in  five  healthy  volunteer subjects.  They  found  that  first 
injection  of  Mephentermine  increased mean  arterial  pressure,  systemic 
vascular resistance, and left ventricular minute work, with no change in the 
other variables. 
In the review done by Warwick D et al (32) they discussed about various 
measures to prevent and treat hypotension. Recent studies support use of α-
agonists such as Phenylephrine. Phenylephrine is more effective and can be 
titrated more easily than ephedrine it may be given as boluses (50–100 μg) or 
by infusion (50–100 μg/min). Brooker RF et al (35) studied sequential infusion 
of Phenylephrine to manage hypotension. In their study also Phenylephrine 
was effective at restoring systolic blood pressure after spinal anaesthesia. Yap 
JC et  al (37) on comparing the efficacy of fluid preloading with two fluid-
vasopressor regimens IV ephedrine boluses was more effective in maintaining 
systolic blood pressure.
 Alahutta S et al (40) studied the effects of Ephedrine and Phenylephrine 
to maintain the systolic arterial pressure 20% above the baseline values during 
spinal anesthesia for cesarean section. In this study also both the vasopressors 
restored maternal arterial pressure effectively. 
Side effects:
The Heart rate remained generally low in Phenylephrine group when 
compared  with  Ephedrine  and  Mephentermine  group.  Seven  patients 
developed bradycardia in Phenylephrine group compared with five and three 
patients in Ephedrine and Mephentermine groups and they were subsequently 
treated  with  Inj.Atropine  0.3  mg  IV  bolus.  Out  of  seven  patients  who 
developed  bradycardia  in  Phenylephrine  group,  five  of  them  developed 
bradycardia after the administration of the drug. One patient in ephedrine and 
Mephentermine group developed tachycardia and two patients in ephedrine 
group  developed  hypertension.  The  incidence  of  tachycardia  is  more  in 
ephedrine and Mephentermine groups than in Phenylephrine group. This is 
due  to  both  direct  and  indirect  action  of  ephedrine  and  Mephentermine 
compared  with  Phenylephrine  which  has  only  direct  α  action.  This  direct 
action  of  Phenylephrine  is  also  responsible  for  the  increased  incidence  of 
bradycardia as seen in our study.
In the quantitative systematic review of seven clinical trials, Anna Lee 
et al  (16) they found that maternal bradycardia was more likely to occur with 
Phenylephrine than with Ephedrine. In a review article by Ngan Kee et al (18) 
they found that Ephedrine causes maternal tachycardia when compared with 
Phenylephrine which causes decrease maternal heart rate. Cyna AM et al (19) 
in their review of 75 clinical trials found that high rates or doses of Ephedrine 
may increase tachycardia incidence.
 David Cooper et  al  (21) on comparing compared Phenylephrine and 
Ephedrine they found that the mean heart rate was higher in Ephedrine group 
than in the Phenylephrine group or the combination group. Lauckner W et al 
(22) found that  when Mephentermine  was used to  treat  hypotension during 
SAB for LSCS, Systolic and diastolic blood pressure increased significantly 
with  out  changes  in  heart  rate. Smith  N et  al  (27) investigated  circulatory 
effects of single intravenous injections of 0.75 mg/kg Mephentermine in five 
healthy  volunteer subjects.  They  found  that  the  first  injection  of 
Mephentermine increased mean arterial pressure, systemic vascular resistance, 
and  left ventricular  minute  work,  with  no  change  in  the  other  variables 
including  heart  rate.  They  finally  concluded  that  for  a  given  increase  in 
arterial pressure, it produces much less drastic changes in other cardiovascular 
variables. 
Mercier FJ et al (28) in their review concluded that Ephedrine has been 
the vasopressor of choice for long, but has a weak prophylactic efficacy and 
also it can induce maternal cardiovascular adverse effects like tachycardia and 
hypertension.  Also  prophylactic  Phenylephrine,  with  or  without  ephedrine 
according to maternal heart rate, is at least as effective as ephedrine, with less 
adverse effects.
 Emmett RS et al (29) also on reviewing 27 trials found that Ephedrine 
is associated with dose-related maternal hypertension and tachycardia. When 
comparing the hemodynamic effects of ephedrine alone  with ephedrine and 
colloid for the treatment of hypotension Critchley LAH et al (1995) (34) found 
that Ephedrine  was  not  a  potent  arterial  vasoconstrictor  and  SAP  was 
maintained mainly by increases in stroke index and heart rate.
On comparing three methods (preloading,  infusion of  ephedrine and 
Metaraminol)  in  preventing  hypotension  during  subarachnoid  anaesthesia. 
Critchley LA et al  (36) found that HR was increased in 12% of patients in 
patients receiving ephedrine. Yap JC et al  (37) on comparing the efficacy of 
fluid preloading with IV Ephedrine, IM Ephedrine and Metaraminol infusion 
found that Heart rate increased by 7% group receiving IV Ephedrine and also 
in group receiving intramuscular Ephedrine. 
In  our  study  5%  in  group-1,  6%  in  group-11,  3%  in  group-111 
developed nausea and vomiting. There was no significant difference among 
the three groups in the development of nausea and vomiting.
In  Dinesh  Sahu et  al’s  (13) study,  10%  patients  in  Ephedrine  and 
Phenylephrine group and 15% patients in Mephentermine group developed 
nausea  and vomiting.  Moran DH et  al  (14) also  found that  there  were  no 
significant differences between the Ephedrine, Phenylephrine groups in the 
frequency of maternal nausea and vomiting.  In  Turkoz A et  al’s  (38) study 
nausea was observed in one patient (6%) in the Ephedrine infusion group and 
nausea and vomiting were observed in 10 patients (66%) in the Ephedrine 
bolus group.
Neonatal outcome:
Casey et al (24) on their retrospective analysis found that Apgar score is 
comparable to umbilical  artery pH in predicting the neonatal outcome. On 
assessing the Apgar score in our study two neonates had Apgar of 6 in group-I 
and II and one neonate in group-III. At 5 mt, no neonate had an Apgar score 
of less than 7 in all three groups. Moran et al (14) reported in their study with 
one neonate with an Apgar of less than 7 in Ephedrine group compared with 
no neonate in the Phenylephrine group. However at 5 mts, no neonate in the 
Ephedrine  or  Phenylephrine  groups  had  an  Apgar  of  less    than  7.In  the 
studies done by Thomas et al (17), Hall PA et al (39), Alahutta et al (40), Laporta 
et al (15), Ayorinde et al (30) also same results were obtained. All the neonates 
had an Apgar of more than 7 at 5 mts in both Ephedrine and Phenylephrine 
group. In the study done by Dinesh Sahu et al  (13) on comparing Ephedrine, 
Mephentermine and Phenylephrine; they found no untoward effects on fetal 
outcome. In all the three groups the entire neonate had an Apgar of 7 and 
more than 7 at 1st and 5th minute. Kansai et al (23) on comparing the effects of 
IV infusion  of  Ephedrine  and  Mephentermine  found  that  neonatal  Apgar 
scores are comparable in both the groups.
Dosage requirements:
In Group-I: 70% of patients required one, 27% of patients required two 
and 3% of patients required three bolus doses to maintain systolic pressure 
within 20%limit of basal value. In Group-II: 77% of patients required one and 
23% of patients required two bolus doses to maintain systolic pressure within 
20%limit of basal value. In Group-III: 90% of patients required one and 10% 
of patients required two doses to maintain systolic pressure within 20%limit 
of  basal  value.  Phenylephrine  was  most  effective  in  treating  hypotension 
followed by Mephentermine and then by Ephedrine.
Similar results were seen in the study done by  Dinesh Sahu et al  (13) 
with  Phenylephrine  being  most  effective  in  treating  hypotension  on 
comparing  with  Mephentermine  and  Ephedrine.  Thomas  DG et  al  (17) 
concluded  that  in  Ephedrine  and  Phenylephrine  groups  median  (range) 
number of boluses of Ephedrine and Phenylephrine was similar. Kansai A et 
al (23) compared the effects of IV infusions of Ephedrine and Mephentermine 
and found that the amount of vasopressor required were statistically similar in 
both groups. 
Thus all the vasopressors effectively maintained the pressures within 
25% of baseline values; Phenylephrine maintained it effectively with fewer 
doses followed by Mephentermine and Ephedrine. 
SUMMARY
This double blind prospective randomized control study was designed 
to evaluate the efficacy of Ephedrine, Mephentermine and Phenylephrine in 
treating  hypotension  during  spinal  anaesthesia  for  cesarean  section.  The 
incidence of undesirable side effects and neonatal outcome in terms of Apgar 
score were also studied.
Following observations were made:
1. All the three vasopressors maintained the arterial pressure effectively 
within 20% of baseline values.
2. The mean value  of  heart  rate  was  highest  in  Mephentermine  group 
followed by Ephedrine and Phenylephrine groups.  
3. The mean values of Systolic BP, Diastolic BP and MAP were higher in 
Phenylephrine group followed by Mephentermine group and Ephedrine 
group throughout the study period.
4. Phenylephrine  group  required  fewer  number  of  bolus  doses  when 
compared with Mephentermine and Ephedrine group.
5. The heart rate generally remained low throughout the study period in 
Phenylephrine  group  and  the  incidence  of  bradycardia  was  more  in 
Phenylephrine group when compared with other two groups.
6. The  incidences  of  tachycardia  were  same  in  both  Ephedrine  and 
Mephentermine groups (one case in each group).In Ephedrine group 
two cases developed hypertension compared with no hypertension in 
other two groups. The occurrence of nausea and vomiting were similar 
and comparable in all the three groups.
7. In all the three groups no neonate had an Apgar score of less than 7 at 
5th minute.   
CONCLUSION
In  conclusion,  we  found  that  all  the  three  vasopressors  namely 
Ephedrine, Mephentermine and Phenylephrine are effective in IV bolus form 
in  maintenance  of  maternal  arterial  pressure  within  20% limit  of  baseline 
values,  though  Phenylephrine  has  quicker  peak  effect,  in  comparison  to 
Ephedrine and Mephentermine and it causes reduction in heart rate, which 
may be advantageous in patients in whom tachycardia is undesirable. All the 
three vasopressor had no significant adverse effects on neonatal outcome.
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COMPARISION OF BOLUS EPHEDRINE, MEPHENTERMINE 
PHENYLEPHRINE FOR THE MANAGEMENT OF 
HYPOTENSION DURING SPINAL ANAESTHESIA FOR 
CAESAREAN SECTION-A CLINICAL STUDY
Patient details: Date:
Name/IP No:
ASA:
Age
Indication:
Weight:
G P L A : 
Study group:
Investigation:
Hb%:
PCV:
Blood Grouping:
Premedication:
Elective  surgery: 
Emergency Surgery:
VP(GIVEN) 2 4 6 8 10 15 20 25 30
T.Ranitidine:  150mg 
PO                            Inj 
Ranitidine: 50 mg IV
T.Metaclopramide: 
10mg  PO 
Inj Metaclopramide: 10 
mg IV
-2  hrs  before  elective 
surgery                    -30 
mts  before  emergency 
surgery.
Preloading:
• Ringer  Lactate: 
15 ml/kg
Base line values:
HR:
SAB:
Position:
Space:
HR
SBP
DBP
MAP
SPO2
Hypotension:                                                             Bradycardia:
Time of onset SAB Time of onset 
Lowest Sys BP recorded After SAB 
Total no of Boluses After  VP 
Total dose of VP used Treated with 
 APGAR Score:
First minute
5th  minute
 Tachycardia: 
Hypertension
:
Time of onset
     After SAB
       After VP
 Timing:
SAB 
Incision
Delivery 
 Onset:
 
Nausea 
Total IVF
vomiting U/O
